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In this presentation it is demonstrated that the unique magnetic properties of 
superparamagnetic cobalt-spinel ferrite nanoparticles can be employed in several novel 
applications.  A method to selectively capture and remove pathogens from infected 
organisms to improve longevity is presented.  Evidence is provided to show that 
automated methods using modified forms of hemofiltration or peritoneal dialysis could 
be used to eliminate the particle/pathogen or particle/infected cell conjugates from the 
organism postoperatively.  It is shown that disparately functionalized nanoparticles can 
be used in concert as drug carrier and release mechanisms.  Lastly, we provide 
preliminary evidence to support the use of magnetic nanoparticles for controlling 






 The patent intent of my body of research was to uniquely conceive and 
analytically substantiate a variety of applications for nanoscale materials having special 
magnetic properties, henceforth referred to as magnetic nanoparticles (MNPs).  
Magnetic nanoparticles are an attractive therapeutic tool for a number of reasons.  
Their size (i.e. measured in nanometers) gives them the ability to distribute ubiquitously 
throughout an infected organism and seek out pathogens wherever they reside.  They 
have unique magnetic properties
1, 2
 that provide a targeting mechanism and a means by 
which to eliminate them postoperatively.  They can be easily coated with biocompatible 
substances to increase their biopersistence.
3, 4
  Their surfaces can be functionalized, and 
the polymers can be selected based on their ability to improve particle solubility in a 
particular fluid or to regulate its biodistribution.  Many biological applications have been 
proposed for magnetic nanoparticles over the last few decades and some continue to be 
active topics of research.
5
  
 Two of the more common applications being researched for magnetic 
nanoparticles are diagnostics and drug delivery.  Several studies have shown that 
functionalized nanoparticles are capable of targeting pathogens and binding those 
pathogens to enhance their detection.
6-9
  The magnetic properties of these particles also 
facilitate their localization to tumor sites or other areas within the body in need of 
therapy making them attractive drug transports.  Novel conjugation strategies have 
been designed to tether the therapeutic package to the particle using bioconjugation 
chemistry.
1
  After being carried to the target site the therapeutic payload must be 
 2
released.  Some release strategies rely on the disparate physiological conditions in the 
intracellular and extracellular spaces.  Using pH labile bonds means that the payload can 
be released when the particle moves between pH conditions.
10
  Disulfide bonds have 
been used because they are readily cleaved by the highly reductive intracellular 
environment.
11
   
 Although some groups are finding that the in vivo deployment of magnetic 
nanoparticles has no toxicological effects
12
, this area has not been heavily researched 
and is much in need of further attention.  Various surface coatings have been applied to 
the particles to enhance their biocompatibility.
4
  Coatings like Dextran, and PEG have 
dramatically increased the particle’s half-life in vivo. However, the bondings between 
the coating and particle surface may rely on non-covalent interactions that lead to 
shorter shelf lives.  In addition, adding functionalities to polysaccharides like Dextran 
can involve the use of highly toxic reagents like epichlorohydrin.  It may be possible to 
identify similar polymers that do not require the use of toxic reagents during 
functionalization and that bind to the nanoparticle surface more securely.   
 Another area that has not received much consideration is the elimination of the 
nanoparticles from the body after their therapeutic tour is complete.  Currently, most of 
the suggested procedures are surgical in nature and highly invasive.  Minimally invasive 
techniques could increase social acceptance of using nanoparticles in biomedical 
procedures.    
Fundamentals 
 In order that the reader may more clearly comprehend the direction of my 
research I have included several brief topic reviews.  These topics include a description 
of the crystal structure of the nanoparticles that I work with, the magnetic properties of 
these nanoparticles and how they are measured, the rationale and approach behind 
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making them biocompatible, and the strategies used to add functionalities to them.  In 
addition this chapter contains reviews on metastatic cancer and the characteristics of 
the HIV-1 virus and its lifecycle so the reader may understand the applicability of the 
research.  Lastly, there is a section that describes chalcogenides, which is a family of 
elements used in my research for their exquisite chemical bonding properties and a 
section on the chemiluminescent properties of Luminol.  The chemiluminescent section 
is being provided to clarify a proof of concept that I designed to show that magnetic 
nanoparticles could be used to control reaction kinetics ad libitum. 
Spinel Ferrites 
The magnetic nanoparticles we developed are known as spinel ferrites with a general 
composition formula of MFe2O4 (M = Mn, Mg, Zn, Co, Fe and other divalent cations or a 
mixture of these cations).
13
  Due to the high compositional flexibility, spinel ferrites offer 
great opportunities for designing and fine-tuning the magnetic properties of 
nanoparticles based upon the magnetic interactions at the atomic level and the crystal 
chemistry.  Russell-Saunders couplings between the cations on the lattice sites of the 
metals making up the spinel structure dictate its magnetic properties.  Magnetic 
coupling is affected by the distance between lattice sites, the magnetic moments, and 
the symmetry of those moments.  The nanoparticles used throughout my studies were 
cobalt ferrites.  They were synthesized using a microemulsion technique that will be 
explained below and their spinel structures were verified using x-ray diffraction.
14
  The 
purity of the sample and size determinations can be made using this technique.  Particle 
size estimates can be made based on peak broadening and calculating the area under 
 4
the curve.  Transmission electron microscopy was also used to make size 
determinations.  
Reverse Micelle Synthesis 
 In the microemulsion technique, the spinel ferrite particle precipitates from an 
organic-based salt solution.  The solution contains amphiphilic organic compounds 
called surfactants that aggregate to form a micellar structure that acts as an incubation 
chamber for the burgeoning particle.
15
   
Superparamagnetism 
 The important point to remember about superparamagnetic behavior is that 
particles that express it become magnetized in the presence of a magnetic field and 
remain demagnetized when it is withdrawn.  This characteristic is ideal for biomedical 
applications where the aggregation of particles infused systemically may be undesirable 
until they are to be eliminated.  Magnetism is essentially about magnetic dipoles and 
how they are arranged in a material.  In ferromagnetic materials there is a partial 
alignment of dipoles in the absence of an external magnetic field.  In ferromagnetic 
materials the dipoles are arranged in two opposite directions but one of these directions 
has more constituent dipoles than the other giving the material an effective net 
magnetization when there is no external magnetic field.
16
  In antiferromagnetic 
materials dipoles are all antiparallel to one another making the net magnetization zero.  
Above a certain temperature, called the Curie temperature, the magnetic properties in 
ferromagnetic and antiferromagnetic materials change because the force from thermal 
oscillations is greater than force between the aligned dipoles.  The alignment of the 
dipoles is lost as the thermal oscillations cause them to rotate in different directions.  A 
material having fewer dipole moments has less dipole interaction energy to overcome 
 5
and the disruption of the dipole alignments can occur at lower temperatures.  This 
disruption leads to randomly oriented dipoles that can align with the magnetic field, 
which is a property referred to as paramagnetism.  When paramagnetism exists below 
the Curie temperature at ambient temperatures it is called superparamagnetism.  
Superparamagnetism can be seen at ambient temperatures in nanoparticles with 
diameters of 10 nm or less.
16
  At this size the magnetic materials have been reduced to a 
single magnetic domain expressing a single magnetic dipole and highly susceptible to 
agitation by thermal energies. 
 Superparamagnetism can be verified using a hysteresis loop like the one 
featured in Figure 1.1.  Hysteresis loops typically compare the induced magnetization 
(M) to the strength of the applied external magnetic field (H).  The magnetic field 
density B: can supplant the induced magnetization value (M) as seen in the figure.  
Remanence and coercivity can be determined from the hysteresis loop.  Remanence is 
the magnetization that remains in the material once the magnetic field is removed and 
coercivity is the magnetic field strength needed to be applied in the opposite direction 
to return the material’s magnetization to zero.  Hysteresis is the work done on a magnet 
and is defined as the width of the hysteresis loop.  The hysteresis measurements taken 
by our group to determine the magnetic properties of our synthesized magnetic 
materials were taken using a superconducting quantum interference device (SQUID) 








Figure 1.1:  Hysteresis loop. 
                                                                                                                                                                                            
Biocompatible Coatings 
 The nanoparticles are coated with a polysaccharide polymer to increase their 
biocompatibility.  This technique provides the advantage of diminishing an immune 
response to the particles since glycans do not typically illicit such a response.
18
  The 
polymer coating used also contained numerous free hydroxyls that willingly form 
hydrogen bonds in aqueous solution.  In concert, the many surface hydroxyls hold the 
particle and surface coat in suspension for an indefinite period of time.  This ability is 
important if the goal is to inject the particles into the general circulation or the ascities 
fluid of the peritoneal cavity.  The surfaces of the polymer can be functionalized with 
molecules (e.g. antibodies, peptides, or aptamers)
4
 that can direct them to specific sites 




Nanoparticle Functionalization and Bioconjugate Techniques 
 7
 Fundamentally, nanoparticle functionalization entailed understanding the 
surface chemistry of the MNP and finding practical conjugation techniques that would 
allow me to modify it.  Many of the applications I was developing for the MNPs required 
that they be deployed in vivo which required the selection of innocuous coatings or 
functions.  Several of the techniques that were adopted and found well suited to my 
needs were techniques that had been employed in protein chemistry and 
pharmacology.  The chemical procedures are explained in detail in Chapter 2.  In theory, 
anything can be considered toxic in sufficient dosages.  Toxicity studies endeavor to 
discover the acceptable level of tolerance for a specific compound.  With regard to our 
nanomaterials, we wanted to provide functionality while abrogating any adversarial 
interactions to avoid crossing the toxic threshold.  Using coatings previously determined 
as harmless by the pharmaceutical industry to cover the indiscernibly noxious surface 
was a good way to head off potential complications until we could test for toxicity.  
Coating the particle had the added benefit of increasing its solubility and available 
points of conjugation.  
Metastatic Cancer and the Nature of Ovarian Carcinomas 
 In 2005, cancer was responsible for 13% of the deaths worldwide (World Health 
Organization).  The types of cancer contributing the highest mortality rates were lung, 
stomach, liver, colon, and breast.  Often, the lethality of cancers is not due to 
tumorigenesis at the original locus but to the establishment of distant foci by malignant 
cells that exfoliate from the primary tumor.  This exfoliation and migration is referred to 
as metastasis and can take place when the tumor is ruptured during surgical 
intervention or when the malignant cell experiences morphological changes that affect 
its adherence to other malignant cells at the tumor site.  Metastases can lead to a 
variety of complications.  Brain metastases, for instance, usually develop at a late stage 
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in the progression of certain carcinomas but can have catastrophic effects on cognitive 
function.  Bone metastases typically have a very poor prognosis and are often incurable.  
Metastases into bone can lead to osteolytic lesions that are typified by nerve-
compression syndromes, fractures, severe pain, and terminal hypercalcemia.
21
  Lung, 
breast, kidney, melanoma, and colorectal carcinomas have been shown to metastasize 
into the central nervous system (CNS) and it is believed that 10-30% of solid tumors 
follow this same metastatic path.
22
  15-30% of lung, bladder, uteran, rectal, colon, renal, 
and thyroid cancers metastasize to the bone and the percentage is as high as 70% for 
breast and prostate cancer.
21
  Current modalities for metastatic cancers include surgical 
excision, and various types of radiation, chemo, and antibody therapies.
23, 24
  Radiation 
therapy can lead to fibrosis.
25
  Prophylactic cranial irradiation (PFI), a standard-of-care in 
CNS metastatic cancer prevention, can lead to adverse neurocognitive disorders.
24
  
Surgical excisions are often incomplete and leave behind residual cancer mass.  Chemo 
therapies lack efficient targeting strategies and often result in collateral damage to 
surrounding tissues. 
 The objective of my research has been to develop a modality aimed at the 
deterrence of the metastatic development of certain carcinomas.  The approach we are 
using involves functionalizing magnetic nanoparticles with peptides, aptamers, 
antibodies, or ligands that target receptors that are uniquely expressed by metastasizing 
cancer cells and extracting those cells magnetically from the organism before they have 
a chance to establish new foci.  Our initial targeting and extraction trials were tested on 
ovarian cancer cells.  Ovarian cancer is one of the most lethal of all gynecological 
malignancies.  While the 5-year survival rate for patients with late stage disease sits 
around 20%, the survival rate for patients diagnosed with early stage disease climbs 
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impressively to 94%.  Thus, there is an urgent need for improved treatment strategies 
for late stage disease.    
HIV-1 Life Cycle and Structural Characteristics 
 HIV-1 is a member of the Retroviridae family.  All retroviruses contain the gag, 
pol, and env genetic sequences that are necessary for expression of the capsid, 
accompanying enzymes, and the viral envelope respectively.  The HIV-1 genome also 
contains additional important sequences.  The rev sequence produces proteins that 
trigger the export of unspliced HIV-1 mRNA from the nucleus to be used in viral 
progeny.  The tat sequence codes for a gene specific elongation factor that greatly 
accelerates the transcription of viral mRNA.  The vif sequence is essential for proviral 
synthesis following viral entry. 
26-28
 The prerequisites for HIV-1 infection include the 
uncoating of the virus, reverse transcription of viral RNA, transport of the preintegration 
complex to the nucleus, and integration of the provirus (viral DNA) into the host 
genome (Figure 1.2). 
 The env sequence, responsible for producing the proteins that make up the 
capsid, expresses the p24 protein.  It has been determined that every HIV-1 capsid 
contains 2000-4000 p24 proteins and this protein is often used to verify HIV-1 
infection.
29
  This means that once the viral coat and capsid are lysed an immunoassay 
like an ELISA can be used to detect quantitative levels of p24 protein and these figures 






Figure 1.2:  Lifecycle of the HIV-1 virus. 
 
Chalcogenide Bonding 
 The chalcogen classification is made up of the Group 16 elements of the periodic 
table.  A subset of this group that is membered by the sulfides, selenides, and tellurides 





them a high redox potential.  Disulfide/thiol redox reactions and the presence of 
selenides have been found to be essential to many biological processes.
30-32
     
Dichalcogenide bonds are single covalent bonds that are formed when two of any 
combination of the protonated chalcogens (thiol (S-H), selenol(Se-H), or tellurol groups 
(Te-H)) are bound through oxidation.  When the electron configuration is such that a 
shell is more complete it becomes harder for an atom to gain or lose an electron.  In the 
 11 
case of the chalcogens the valence shell for each requires two additional electrons to fill 
the p orbital.  However, it is not the need for additional electrons that is responsible for 
differences in bonding behavior between the dichalcogens.  The atomic size, 
electronegativity and R groups bound to the chalcogen have a tremendous effect on 
their bond strengths.  Depending on the R group, steric hindrance can lead to rotational 
barriers that affect the electronic structures of the molecules.  Kaur et al. 
33
 showed that 
for a dichalcogenide bond X-X and X-R, where X = O, S, Se and R = H, CH3, or NH2, bond 
lengths were greatest when X = Se and shortest when X = O.  However, when X = O and 
R = CH3 or NH2 the bond lengths almost increased to a non-bonded length.  This was not 
the case when X = S or Se and was explained as being a result of differences in the 
dihedral angles which were 90 degrees for H-X-X-H when X = S or Se and 120 degress 
when X = O.  When X = O the dihedral angle was larger as a result of hydrogen bonding 
interactions between the O and H from non-covalently bound O-H groups.  When X = S 
or Se the dihedral angle was determined by lone-pair lone-pair and bond-pair bond-pair 
repulsions.  Kaur et al. 
33
 also looked at the hemolytic bond dissociation energy (BDE) for 
the chalcogens mentioned and found that the X-H BDEs were larger than those for H-X-
X-H and the values were greatest when X = O and least when X = Se.  The BDE levels for 
H-X-X-H were found to be highest when X=S and lowest when X = O which showed no 
dependence on the atomic radius of the chalcogen.  However, atomic radius was 
inversely proportional to the BDE values for H-X-CH3.  Overall, the data showed that 
dichalcogen bond strengths were greatest for disulfides and weakest for dioxides.  
These BDE values explain why the pKa for a selenol is 5.3 and the pKa for a thiol is 8.25.  
Less energy would be required to deprotonate the hydrogen of a selenol.   At a neutral 
physiological pH a selenol will become a selenate which is the form necessary to reduce 
a dichalcogenide bond. 
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Chemiluminescence and Luminol 
 The chemiluminescent reaction featured in Figure 1.3 shows how luminol is able 
to emit quanta of visible light.  In alkaline solution the secondary amine groups are 
deprotonated by the hydroxides in solution.  Electron transfers take place between the 
dianion that is formed and the carbonyl groups forming an enolate.  If oxygen is 
introduced into the reaction at this point it reacts with the dianion to form an unstable 
organic peroxide that liberates nitrogen gas.  Electron transfer takes place once more 
and carboxylate anions are formed resulting in 3-aminophthalate.  The cleavage of the 
organic peroxide results in an energy gain and effectively leaves 3-aminophthalate in an 
excited state which decomposes releasing a quantum of visible light. 
34
  
 It should be noted that throughout the mechanism featured in the diagram the 
primary amine remains intact.  It was for this reason that it was chosen as a conjugation 
point for the reaction impedance experiment described in the Appendix.  The initial 
supposition was that binding luminol at this point should not adversely affect its 










EXPERIMENTAL APPROACHES AND METHODS 
 This chapter provides a detailed overview of the experimental designs and 
methods used throughout the studies described in subsequent chapters.  The 
explanations provided should serve as reference when reading the pertinent study in 
later chapters. 
Experimental Approaches 
Drug Delivery Application 
 In vitro experiments were conducted to verify that the particle/package 
conjugate linked by the dichalcogenide bond could be separated using the described 
mechanism.  In the control group (Figure 2.1) the lability of the dichalcogenide bond was 
tested using a non-functionalized magnetic nanoparticle.  In the experimental group 
(Figure 2.2), a nanoparticle with a thiol or selenide group was used to cleave a selenyl 
sulfide or tellurol selenide link respectively.  Fluorescein and Luminol were used as 
packages because their release was visibly detectable using fluorescent microscopy.  
Acetasalisylic acid was used as a package simply to show that a drug could be 
conjugated to the particle surface.  No studies were conducted to determine whether 
the conjugation strategy adversely affected the drug’s normal function. 
 
X = S when Y = Se  
X = Se when Y = Te 
 
Figure 2.1:  Schematic of control group used in drug delivery experiments.  The values 
listed for X and Y illustrate two types of dichalcogenide bonds used to conjugate 
packages to the nanoparticle surface (#1).  The control particl
chalcogenide functions. 
 
X = S when Y = Se  
X = Se when Y = Te 
 
Figure 2.2:  Schematic of experimental group used in drug delivery experiments.  The 
values listed for X and Y illustrate t
packages to the nanoparticle surface (#1).  The control particles (#2) had chalcogenide 
functions. 
 
 The logistics of the experiments were roughly the same for each permutation.
volume of nanoparticles bound to one of the previously mentioned packages was 
introduced to a reaction 
nanoparticle, having or not having been previously conjugated to a chalcogenide 
function, depending on the group, was also introduced to the reaction vessel (F
2.3.A).  A magnet was placed beside the vessel to bring the nanoparticle carrier and 
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PACKAGE = Fluorescein, Luminol, Acetasalisylic A
es (#2) had no 
 
PACKAGE = Fluorescein, Luminol, Acetasalisylic Acid
wo types of dichalcogenide bonds used to conjugate 
vial containing aqueous solution (Figure 2.3.A).  
cid 
 
  A 
Then a second 
igure 
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nanoparticle release mechanism together (Figure 2.3.B).  The magnetic filtrate was 
examined for traces of the released package (Figure 2.3.C).  Three analytical techniques 
were used to verify the structure of the reaction components and the release 
mechanism.  Fluorescent microscopy was instrumental in visually verifying that 
fluorophores had been attached to the nanoparticle surfaces and whether or not they 
were being released.  Variations between the UV/Vis spectra obtained from samples at 
various stages of the conjugation and release process were used to substantiate 
changes in sample properties.  Spectra of the pure compound being conjugated to the 
nanoparticle, the unconjugated nanoparticle itself, and the conjugated 
nanoparticle/compound were taken separately and used as baseline comparisons to the 
magnetic filtrand and filtrate spectra.  HPLC/Mass Spectrometry was used to locate the 
released compound in the magnetic filtrate.    
 A modification was made to the fluorescent microscopy experiment by 
incorporating a peristaltic pump driven extracorporeal circuit with an integrated 
capillary tube that passed over the microscope objective.  This design (Figure 2.4) 
visually illustrated the nanoparticles being captured and the packages being released 
into the circulating flow.  It was also an initial proof of concept showing the plausibility 
of using the mechanism in systemic circulation in vivo. 
 The strategy for creating dichalcogenide linkages between the MNP and the 
packages to be released is thoroughly explained in the next section titled, “Surface 
Modification Strategies.” 
A 
MIXED CARRIER WITH 
RELEASE MECHANISM 
Figure 2.3:  A: Nanoparticles
reaction vial along with a release mechanism
reaction vial to force the nanoparticle/package conjugate to aggregate with the release 
mechanism.  (C)  The filtrate was removed from the reaction vial and examined for 




B C  
APPLIED MAGNET TESTED FILTRATE
 (#1) with package conjugates (red box) were added to the 
 (#2).  B:  A magnet was placed near the 




Figure 2.4:  Basic schematic diagram showing how the drug release mechanism was 
tested using a peristaltic pump driven circuit.  The capillary was placed over the 
objective of the microscope and a magnet was placed next to the capillary tube.  
The nanoparticle (yellow sphere) was pumped through the circuit and could be seen 
collecting against the side of the capillary tube closest to the magnet.      
 
 
Ovarian Cancer Application 
 The experimental designs used to show that ovarian cancer cells could be 
selectively captured using a ligand specific for an ovarian cancer cell membrane receptor 
are thoroughly explained in Chapter 4 which contains the work as it was published in the 
Journal of the American Chemical Society.   
Ascites Study 
 The ascites study was a natural progression from the ovarian cancer study 
previously described.  Ascites fluid from patients with extraovarian peritoneal serous 
papillary carcinoma was collected and donated by the Ovarian Cancer Institute in 
Atlanta, Georgia.  The disseminated tumor equivalent for most patients at the time of 
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sampling corresponded to an ovarian Stage III or IV disease (The International 
Federation of Gynecology and Obstetrics (FIGO) staging system).  An experiment (Figure 
2.5) was devised to identify the resident cell populations in the ascites samples and 
resolve whether the malignant cells could be selectively captured.   
 A sample of the ascites fluid from a patient was first aliquoted equally into three 
vials.  One vial was left untreated and set aside for analysis.  Nanoparticles with peptide 
conjugates were added to a second vial and nanoparticles with no peptide conjugates 
were added to a third.  The solutions in the two vials containing nanoparticles with and 
without peptide conjugates were given equal incubation periods and then magnetically 
separated for equal intervals.  The filtrates were drawn from both vials and placed in 
separate vials for analysis.  The filtrand from both vials was washed 3x with PBS and set 
aside for analysis.  All 5 vials were analyzed using a BD LSR flow cytometer (BD 
Biosciences). 
 
Ovarian Cancer Survival Study 
 The purpose of the ovarian cancer survival study was to discover whether the 
capture and removal of disseminated tumor cells could be employed as a curative 
measure to mitigate metastasis and thereby increase longevity.  
 20 
  
Figure 2.5:  Overview of the experimental design used to verify whether magnetic 
nanoparticles with peptide conjugates were capable of selectively extracting ovarian 





 A murine ovarian cancer cell line (ID8) transfected with the gene for green 
fluorescent protein (GFP) and vascular endothelial growth factor (VEGF) expression was 
used for the study.
35
  VEGF expression would expedite tumor progression by stimulating 
angiogenesis and abating the immune response.  The cell line was obtained through a 
material transfer agreement with the laboratory of Dr.  George Coukos at the University 
of Pennsylvania. 
Cell Rejuvenation 
 Per Zhang et al. 
35
 Dulbecco’s modified Eagle’s medium was supplemented with 
4% fetal bovine serum, 100 U/mL penicillin, 100 µg/mL streptomycin, 5 µg/mL insulin, 5 
µg/mL transferrin, and 5 ng/mL sodium selenite.  The cryogenically frozen ID8 cells were 
slowly thawed at 37⁰ C and transferred to a growth flask containing 10 mL of the 
prepared medium.  Cells were maintained in an incubator at 37⁰ C and a 5% CO2 
atmosphere. 
EphA2 Expression 
 The ID8 cell lines were tested for EphA2 expression to insure that we could use 
the YSA peptide to bind it.  Ovarian cancer cell lines (ID8 GFP, ID8 GFP VEGF, BG1 and 
HEY) were plated and grown in 4 well plates.  The formulation in Table 2.1 was brought 
up to 10 mL using distilled water and was added to each well plate after the removal of 
the growth media.  The contents of the plate were centrifuged at 12000 RPM and 4⁰ C  
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Table 2.1:  Cell Lysis Buffer Formulation     
VOLUME REAGENT CONCENTRATION 
200 µL Tris (pH 7.5) 20 mM 
1.5 mL NaCl 150 mM 
20 µL EDTA 1 mM 
40 µL EGTA 1 mM 
100 µL Triton X-100 1% 
250 µL Sodium Pyrophosphate 2.5 mM 
10 µL β-Glycerolphosphate 1 mM 
20 µL* Na3VO4 1mM 
100 µL* Protease Inhibitors 1 µG/mL 
10 µL* PMSF  
500 µL Glycerol  
*Stored at 4⁰ or -20⁰  
 
for 5 minutes.  The supernatant was transferred to another tube and 10 µL from that 
tube was used to establish the protein concentration using a Bradford assay (optical 
density measured at 595 nm).  These optical density measurements were used to 
calculate the equivalent gel loading volumes for each sample.  The standard procedures 
for Western blot analyses were followed
36
 and the blots were compared to establish the 
relative EphA2 expression level for each sample. 
Peptide Affinity for EphA2 Receptor 
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  The growth medium in well slides containing ID8 GFP and ID8 GFP VEGF cell lines 
was removed and supplanted with 2 mL of 0.1 M sodium phosphate buffer, pH 7.4.  100 
µL of magnetic CoFe2O4 nanoparticles (10mg/ml) in aqueous solution and conjugated to 
the YSA peptide and Rhodamine were incubated with the ID8 GFP and ID8 GFP VEGF cell 
lines in well slides for 10 min.  The slides were washed 3x using the same PBS buffer and 
then fixed in 100% ethanol.  Confocal microscopy (LSM 510 UV, Carl Zeiss Inc.) was used 
to image the slides and verify the presence of the Rhodamine tagged nanoparticles. 
Tumor Model 
 Understanding the metastatic progression of the tumor model being used was a 
prerequisite to designing an experiment to analyze whether the proposed therapy could 
improve longevity.  The tumorigenesis of the ID8 cell line expressing GFP and VEGF was 
compared to that of an ID8 cell line expressing only GFP (Figure 2.6) that served as a 
control.  The results were measured both qualitatively and quantitatively.  Mice from 
each group were euthanized and necropsied at 3-4 time points (2,4,6, and 8 weeks).  
Sections of the liver, lung, spleen, peritoneal wall (1 cm x 1 cm), and the intestines were 
viewed and photographed using both bright field and dark field microscopy on an 
Olympus SZX series stereo scope with green filters (Magnification = 38.5x) and an 
Olympus DP71 12.5 million pixel digital camera.  The GFP being produced by the cells 
made the metastatic sites easy to locate.  The visible fluorescence from the GFP 
produced by the cancer cells facilitated qualitative comparisons of tumor progression 




between the control and experimental groups.  The comparative number of metastatic 
sites was determined quantitatively
running 200 microliters of each in duplicate 
(SPECTRAMAX Gemini, Molecular Devices)
Survival Study 
 The final part of the 
old female C57BL/6 mice
various intervals (Figure 2.7
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 test the metastatic cancer 
 by homogenizing the tissue sections collected and 
through a fluorescence microplate reader 
 to determine their optical densities
study, which is still underway, involved inoculating 
 (Black 6) with the ID8 GFP VEGF cell line and treating them at 








three to four days per week .  When the body mass was found to exceed 150%  of the 
mass taken at the start of the experiment the mouse was euthanized and the optical 
density measurements of the homogenized liver and lung sections were taken using a 
fluorescence microplate reader (SPECTRAMAX Gemini, Molecular Devices). 
Magnetic Filtration Scheme         
 Three elimination schemes were devised to remove the MNPs postoperatively.  
The first (Figure 2.9.A) involved placing a magnetic field at a point exterior to the subject 
being studied and waiting for a period while the particles began to collect in that region.  
This idea was quickly abandoned.  The approach would require that the nanoparticles be 
within a close proximity to the magnetic field and assume that no internal 
encumbrances would block their migration.  Removal of the aggregated particles would 
also be highly invasive requiring the excision of the tissue containing them.  The second 
approach (Figure 2.9.B) consisted of inoculating the subject intraperitoneally with a 
bolus of MNPs and allowing the MNPs to disseminate ubiquitously throughout the 
peritoneum.  The extracorporeal circuit would cycle the fluids in and out of the 
peritoneum.  A magnetic filtration trap would be a component of the external circuit 
where the MNPs would be collected as they were cycled out of the organism.  For 
reasons that will be explained in Chapter 6, it was decided that this technique would not 
be used for the survival study.  Instead, the design featured in Figure 2.9.C was used.  In 
this embodiment the MNPs are introduced externally and never enter the organism.  An 






# MICE 2WK 4WK 6WK 8WK 
CONTROL GROUP I NO TREATMENT 10    
 
CONTROL GROUP II INOCULATED WITH CANCER 
CELLS/ NO TREATMENT 
10   
 
 
CONTROL GROUP III TREATMENT ONLY      
--SUBGROUP I @ 24 HOURS 10    
 
--SUBGROUP II @ 24 HOURS 
@ 2 WEEKS 
10    
 
--SUBGROUP III @ 24 HOURS 
@ 2 WEEKS 
@ 4 WEEKS 
10 
 
   
 
--SUBGROUP IV @ 2 WEEKS 10    
 




INOCULATED WITH CANCER 
CELLS/ TREATMENT 
     
--SUBGROUP I @ 24 HOURS 10    
 
--SUBGROUP II @ 24 HOURS 
@ 2 WEEKS 
10    
 
--SUBGROUP III @ 24 HOURS 
@ 2 WEEKS 
@ 4 WEEKS 
10 
 
   
 
--SUBGROUP IV @ 2 WEEKS 10    
 
--SUBGROUP V @ 4 WEEKS 10    
 
Figure 2.7:  Simplified Gant chart explaining the treatment schedule used for the survival 
study.  Body mass was measured at 2 week intervals.  If the mass > 150% of original 
body mass the animal was euthanized.  External images of peritoneal region were taken 
at 2 week intervals and optical density measurements of GFP content in liver and lungs 




Figure 2.8:  Overview of the Ovarian Cancer Survival 
Inoculating mice with cancer cells expressing GFP facilitated tracking the metastatic 

















them at a particular 
locus. 
 
B:  Nanoparticles are 
injected in vivo and 
then eliminated using 
an extracorporeal 
circuit containing a 




C:  Nanoparticles 
never enter the body 
and mix with bodily 
fluids in a mixing 
chamber prior to 
being separated by a 
magnetic trap.  Fluids 
are cycled using an 
extracorporeal circuit. 
Figure 2.9:  Different schemes for eliminating nanoparticles post-procedurally. 
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Table 2.2:  Equipment used in survival study. 
COMPONENT MEASUREMENTS DESCRIPTION 
Tubing  ID 2.4 mm, OD 4 mm, Wall 0.8 
mm 
Tygon sterile inert tubing.  
Formulation S-50-HL.  Used for 
extracorporeal circuit. 
Needles 20 Gauge 1” Used as cannulas to feed and 
extract fluids  
Extracorporeal circuit  49 in, 9.5 mL Measurements are for the total 
length and volume of the 
combined segments (Figure 
2.10). 
Variable Flow Pump N/A Fisher (PRDT# 138762).  
Peristaltic pump used to cycle 
fluids. 
Magnetic Filter 15 mL Glass vial attached to a magnet. 
Mixing Cartridge 15 mL Glass vial. 
 
 
and the magnetic particles.  The specifics of the design used are provided in Table 2.2. 
Figure 2.10 and 2.11 show the actual setup used during the procedure.  Arrow #1 points 
to two stacked neodymium magnets (2 in x 2 in x 4 in) with a magnetic field strength of 
about 6000 gauss at the surface of each.  The magnetic filtration vial (Arrow #2) was 
strapped to the side of the top magnet.  The vial where the magnetic nanoparticles were 
first introduced (Arrow #3) was placed approximately a foot away from the magnets so 
that it could remain outside of the magnetic field.  Arrow #4 points to the variable flow 
pump.  The pump was set at a flow rate of 10 mL/min.  Arrow #5 points to the outlet 
needle that was used to cannulate the mouse towards the dorsal region of the 
peritoneal cavity.  Arrow #6 points to the inlet needle that was used to cannulate the 
mouse in the ventral region of the peritoneum.  The following procedure was followed 
using the setup as described: 
 
Figure 2.10:  Equipment used in the Ovarian Cancer Survival Study. (1) 6000 
neodymium magnets (2) Magnetic filtration vial (3) Mixing cartridge wher











Figure 2.11:  Measurements for Tygon tubing used in Ovarian Cancer Survival Study.  
Numbers correspond to item descriptions in Figure 2.10. 
 
 
1. The magnetic filtration vial and mixing vial were filled with 15 mL of 
sterile 0.1 M sodium phosphate buffer, pH 7.5, and attached to the 
extracorporeal circuit as shown in Figure 2.10. 
2. The inlet needle was submerged in a beaker containing a sufficient 
volume of sterile 0.1 M sodium phosphate buffer to fill the 
extracorporeal tubing.  The variable flow pump was engaged and ran 
until the fluid had coursed through the entire circuit. 
3. Step 2 of this procedure lowered the volume of the two vials.  The 
volume in the magnetic filtration vial was brought back up to 15 mL using 
the same buffer solution.  The volume in the mixing vial was brought up 
to 14 mL of the same buffer solution and 1 mL of (1g/mL) MNPs 
(conjugated or not conjugated to the YSA peptide depending on whether 
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it was the control or experimental group) were also added to the mixing 
vial to bring its volume to 15 mL. 
4. An anesthetized female C57BL/6 was cannulated in the ventral region of 
the peritoneum using a 20 gauge 1” needle (Arrow #6 Figure 2.10).   
5. The outlet needle was placed in a beaker containing greater than 8 mL of 
sterile 0.1 M sodium phosphate buffer, pH 7.5 and the pump was 
engaged until 8 mL was drawn from the beaker.  It was necessary to fill 
the mouse’s peritoneal cavity with an additional 8 mL of fluid to prevent 
occlusion of the needles during the procedure. 
6. The outlet needle was removed from the beaker and used to cannulate 
the mouse on its left flank toward the dorsal region of the peritoneal 
cavity. 
7. The pump was engaged for 20 minutes and stopped and restarted at any 
sign of occlusion.   
8. After the 20 minute session was complete the pump was shut off and the 
inlet needle was removed and placed into an empty 10 mL graduated 
cylinder.  The pump was re-engaged and the graduated cylinder was 
brought to a volume of 8 mL.  This step was used to insure that the 
excess fluids were completely removed from the mouse. 
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9. The mouse was disconnected from the circuit and the pump was again 
engaged until the tubing and vials were depleted of all fluids.  The 
removed fluids were placed in a falcon tube and centrifuged at 800 RPM, 
4⁰ C for 5 min.  The supernatant was siphoned out of the falcon tube and 
any remaining pellet was resuspended in 200 µL of sterile 0.1 M sodium 
phosphate buffer, pH 7.5.  The 200 µL containing the pellet were injected 
intraperitoneally back into the mouse.  This step eliminated the 
possibility of malignant cell titer reduction from fluids left in the circuit 
which could otherwise be considered a contributing factor to improving 
long-term prognoses. 
HIV Capture Study 
 Preliminary in vitro studies were run to determine whether MNPs could be used 
to reduce viral titer (Figure 2.12).  MNPs coated with glucuronic acid and conjugated to 
anti-gp120 and MNPs coated with glucuronic acid and having no antibody conjugates 
were added to separate aliquots of solutions containing active HIV-1 virus and given a 
set period (Incubation Time) to bind the gp120 viral epitope.  After the set period, the 
colloids containing the virus and MNPs were placed in a magnetic separation apparatus 
(Dynal-MPC, Magnetic Particle Concentrator) and given a set amount of time (Capture 
Time) to collect on the side of the vial closest to the magnetic field.  The magnetic 
filtrate (i.e. remaining solution) was drawn off and tested for p24 concentration using a 
p24 antigen ELISA (ZeptoMetrix Corp.).    Prior to running these studies it was necessary 
Figure 2.12:  Basic concept behind the HIV
 
to determine whether the residual MNPs in the filtrate might affect viral binding to the 
antibodies in the ELISA plate.  The design for each of these experiments is laid out in the 
next three sections.  The micro
Technologies Ultrawash Plus and the microplate reader was a BioTek Instruments Bio
Kinetics Reader EL312e.  The viral sample
and stored by the CDC on 8/26/19
Testing MNP Interference with the p24 Assay
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-1 Capture Study. 
plate washer used in each of the studies was a Dynex 
 used was taken from an undisclosed individual
98.   




 The ZeptoMetrix HIV
determine the p24 concentrations in each of the experiments described in this section.  
For each run of the ELISA assay it is ne
concentrations.  A calibration curve is created from the optical density values obtained 
from these standards and the p24 concentrations of the experimental samples are 
interpolated.  To test the effects of the MNPs on 
in duplicate in the microtiter plate as dictated by the assay.  The first group was left 
unaltered and 20 µL of glucuronic acid coated MNPs (10 mg/mL) were added to each of 
the standards in the second group.  The assay was perf
Zeptometrix and the p24 concentrations of each group were compared.  This 
experiment was repeated using a volume of 10 µL of glucuronic acid coated MNPs (10 
mg/mL).  The data were normalized to account for the dilution of the sample
experimental group.  The results are discussed in Chapter 
HIV-1 Capture Experiment I
 A summary of the conditions of the first experiment are provided in Figure 2.13.
 
Figure 2.13:  Conditions for HIV
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-1 p24 Antigen ELISA (ZMC Catalog# 0801111) was used to 
cessary to include a set of standard 
the assay, the standards were prepared
ormed as recommended by 
7. 
 
-1 Capture Study Experiment I. 
 
 in the 
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The summary shows the number of MNPs that were added to the experimental and 
control vials and the number of viral particles in each vial.  The viral particles were 
suspended in unmodified RPMI cell growth media.  The following procedures were 
performed: 
1. Viral stock BaL 8/26/1998 (1.7 x 1010 vp/mL), having been previously 
stored at -80⁰ C, was thawed at room temperature for 1 hour.   
2. The viral concentration was reduced to a level detectable by the 
ZeptoMetrix HIV-1 p24 Antigen ELISA by performing a 1:9550 dilution 
with RPMI which provided an approximate concentration of 625,000 
vp/mL or 62.5 pg of p24/mL.
29
  To perform the dilution 1 µL of the viral 
stock was added to 954 µL of RPMI.  The diluted viral solution was 
vortexed for 1 min (Vortex Genie 2) and then aliquoted into 14 tubes (50 
µL/tube).  450 µL was added to each tube.  The 14 tubes were vortexed 
for about 30 sec each and labeled S1A-S1B for control group I, S2A-S2F 
for control group II, and S3A-S3F for the experimental group. 
3. 10 µL of MNPs (10 mg/mL) without anti-gp120 antibody functions were 
added to each tube in control group II (S2A-S2F) and the contents were 
vortexed briefly (≈ 10 sec).  Each tube was left at room temperature to 
incubate for 10 min. 
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4. 10 µL of MNPs (10 mg/mL) with anti-gp120 antibody functions were 
added to each tube in the experimental group (S3A-S3F) and the 
contents were vortexed briefly (≈ 10 sec).  Each tube was left at room 
temperature to incubate for 10 min. 
5. The tubes (S2A-F and S3A-F) from control group II and the experimental 
group were placed in magnetic bead separators (Dynal-MPC) for 10 min. 
6. Without removing the tubes from the magnetic bead separators, 450 µL 
was extracted from each tube and placed in a new tube with the same 
label. 
7. 50 µL of solution was removed from tubes S1A and S1B and discarded. 
8. Tubes S1A-S1B, S2A-S2F, and S3A-S3F were ready to be assayed 
following the procedures outlined in the Zeptometrix HIV-1 p24 Antigen 
ELISA kit. 
HIV-1 Capture Experiment II 
 The procedures conducted in this experiment were similar to those conducted in 
HIV-1 Capture Experiment I but it was conducted under different conditions and an 
additional experimental group was added.  A summary of the conditions for this 
experiment has been provided in Figure 2.14.  As before, the summary shows the 
number of MNPs that were added to the experimental and control vials and the number 
of viral particles in each vial.  The viral particles were suspended in unmodified RPMI cell  
Figure 2.14:  Conditions for HIV
 
growth media.  The following procedures were performed:
1. Viral stock BaL 8/26/1998
first adding 1 µL of viral stock to 999 µL of RPMI, vortexing the solution 
for 1 min (Vortex
each, and adding 450 µL of RPMI to each tube.  Each tube wa
vortexed for 30 sec each.
2. The tubes for control group I were labeled S1A
control group II were labeled S2A
I were labeled S3A
labeled S4A
3. Control group I tubes S1A
concentration
glucuronic acid coated MNPs (10
conjugates.  Experimental group I tubes S3A
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-1 Capture Study Experiment II. 
 
 (1.7 x 10
10
 vp/mL) was diluted (1:10,000) by 
-Genie 2), aliquoting the solution into 20
 
-S1B and the tubes for 
-S2F.  The tubes for experimental group 
-S3F and the tubes for experimental group II were 
-S4F. 
-S1B were only used to measure p24 
.  Control group II tubes S2A-S2F received 100 µL
 mg/mL) having no anti-
-S3F received 
 
 tubes of 50  µL 
s then 
 each of 
gp120 antibody 
50 µL each of 
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glucuronic acid coated MNPs (10 mg/mL) with anti-gp120 antibody 
conjugates.  Experimental group II tubes S4A-S4F received 100 µL each of 
glucuronic acid coated MNPs (10 mg/mL) with anti-gp120 antibody 
conjugates.   
4. Tubes S2A-S2F, S3A-S3F, and S4A-S4F were incubated at 37⁰ C for 30 min 
after adding the MNPs to the tubes.  
5.  The capture time was performed for 10 min as described in HIV-1 
Capture Experiment I. 
Reaction Impedance Study 
 The purpose of this study was to provide a visual proof of concept demonstrating 
the viability of using MNPs to control reaction kinetics.  The reaction being controlled 
was the chemiluminescent reaction involving luminol.  The experimental design was 
simple.  Nanoparticles conjugated to luminol were added to a solution containing the 
necessary reactants to produce light.  A magnet was used to pull the MNP/luminol 
conjugates from solution to halt light production.  The conjugation strategy used to bind 
luminol to the surface of the MNP is covered in the next section.  The following 
procedures were followed to create the reaction solution: 
1. A stock solution of dilute household bleach (Stock A) was created by 
adding 10 mL of household bleach to 1 L of distilled water.   
2. 10 mL from Stock A was added to 5 mL of 0.1 M NaOH in a reaction vial. 
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3. A 2000 gauss magnet was placed beside the reaction vial and 100 µL of 
the MNP/luminol conjugate were pipetted into the vial.  
Surface Modification Strategies 
 There are a plethora of conjugation strategies suitable for binding biocompatible 
coatings and ligands to the surface of nanoparticles.
38
  The methods that will be 
presented here are the few that I found to be the most useful and convenient for my 
particular needs.  In many of the described procedures it is mentioned that the samples 
were resuspended in distilled water.  For in vitro applications aseptic conditions were 
unnecessary but when preparing samples for in vivo use the water was always sterilized 
(Barnstead PVdry2 Sterilizer) and the conjugations took place within an air purifier 
(Labconco Purifier Delta Series Class II) to mitigate the pyrogenicity or immunogenicity 
of the sample.  In addition, unless otherwise stated, all conjugations took place at 
ambient temperature.  Nanoparticles conjugated to peptides and antibodies were 
always stored, post-conjugation, at 4º C. 
 
Surface Binding with Carboxyl Groups and Hydroxyl Groups 
Hydroxyl Group Conjugations 
 Some polymers, like Dextran, that were used to coat nanoparticles relied on 
hydrogen bonding interactions to remain adsorbed to the MNP surface.  Hydrogen 
bonds are much weaker than ionic or covalent bonds and often lead to disaggregation 
of the coating over short periods.  To retard disaggregation some groups employed a 
highly toxic reagent to crosslink the Dextran molecules.  The cross linking created a 
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mesh of Dextran around the particle that was more stable but the procedure had to be 
performed in a fume hood and purification of the product was paramount before it 
could be used in vivo.  I initially started working with Dextran in the early stages of my in 
vitro studies but quickly abandoned it in search of another more stable polysaccharide 
coat that would have the same non-immunogenic properties and be easier to work 
with.   
Dextran 
 The MNPs were coated with Dextran by adding 200 mg MNPs to 2.5 mL of 0.5 M 
NaOH (Vial 1).  In a separate vial (Vial 2) 200 mg of Dextran was added to 2.5 mL of 0.5 
M NaOH.  The 0.25 “ diameter sonication tip from a Sonics Vibra Cell sonicator was 
lowered into Vial 1 below the liquid surface level and the solution was sonicated for 15 
min with a temperature setting of 25⁰ C and a 38% Amplitude.  After 15 minutes, Vial 2 
was added to Vial 1 without stopping the sonication process and the combined solutions 
were sonicated continuously overnight.  The sample was magnetically filtered using a 
2000 gauss magnetic, washed 3x using distilled water, and resuspended in same.  
 
Carboxyl Group Conjugations 
 Prior to conjugating the nanoparticles to molecules with carboxyl functions, the 
hydroxyl groups on the surface of the nanoparticle needed to be deprotonated.  This 
was typically done by adding the nanoparticles to a solution of 5 M NaOH and sonicating 
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the MNPs for 30 min with a Fisher Sonic Dismembrator 60 at a power setting of 13.  Post 
sonication the compound having carboxyl functions would be added to the alkaline 
solution.  If the molecule contained multiple carboxyl groups it would be added in a 
molar excess of 10-100 fold to that of the nanoparticles.  The molar excess was 
necessary to limit polymerization of the product and insure adequate surface coverage 
of the nanoparticle.  The alkalinity of the solution acts to dissociate the carboxylic 
function on the ligand to a carboxylate anion which coordinates with the particle 
surface. 
 
Terepthalic Acid Coatings 
 Terepthalic acid was a molecule used to conjugate luminol to the surface of the 
MNPs.  This molecule was chosen as a linker molecule because its carboxylate anion 
could form an amide bond with luminol’s primary amine group.  The amide would then 
contain a carbonyl that could act as a hydrogen acceptor and a secondary amine that 
would act as the hydrogen donor promoting the solubility of the conjugate.  
 To add terepthalic acid to the surface of the MNPs, 70 mg of CoFe2O4 and 300 
mg of terepthalic acid were added to a 70% ethanol solution and sonicated for 2 hours 
(Fisher Cell Dismembrator 60, Power Level = 13).  The solution was left to incubate at 
room temperature overnight without stirring or sonication.  The reaction vial contained 
a grey precipitate the next day.  The precipitate was magnetically filtered and washed 3x 
to remove the ethanol and unbound terepthalic acid.  The washed MNPs were then re-
suspended in distilled water and the procedure described under coupling carboxyls to 
amines was used to conjugate the luminol to the particle surface.  
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Polygalacturonic Acid Coatings 
 Polygalacturonic acid is a form of polymerized galacturonic acid.  The molecule is 
more commonly known as pectic acid and is a constituent of all plant cell walls.  The 
molecule is made up of a linear chain of galacturonic acid units bound together by 1α-4 
glycosidic links.  Galactose is a glucose analog and polygalacturonic acid is similar to 
Dextran but also contains carboxyl groups attached to the 6th carbon of the 
galacturonic acid rings.  Alone, polygalacturonic acid is virtually insoluble in aqueous 
solution but capping its carboxyl groups with hydrophilic molecules promotes its 
solubility in aqueous solution.  A typical polygalacturonic acid molecule possesses many 
carboxyl functions and it is necessary to introduce them in molar excess over the 
number of nanoparticles they are being conjugated to.   
  The conjugation of polygalacturonic acid to the cobalt ferrite surface was simple 
and straightforward.  The nanoparticle hydroxyls were deprotonated in 5 M NaOH at a 
concentration of 1-10mg/mL as previously mentioned and 30 mg/mL of the glycoside 
was added to the solution.  The solution was sonicated for 2-3 hours (Fisher Sonic 
Dismembrator 50 – Power Level of 13).  Post-sonication the sample was magnetically 
purified and washed with 0.1 M sodium phosphate buffer three times before being 
resuspended in distilled water. 
 
Glucuronic Acid Coatings 
The glucuronic acid molecule is also a glucose analog and contains a single carboxyl 
group at carbon 6.  Polymerization was not a concern when conjugating this molecule to 
the MNP surface and smaller molar ratios could be used. 
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Coupling Carboxyls to Amines  
 When the hydroxyl of a carboxyl group is supplanted with an amine, an amide is 
formed (R1(CO)NR2R3).  Several characteristics of the amide bond make it an attractive 
method of conjugating ligands for use in vivo. The bond is stable under physiological 
conditions.  Amide hydrolysis typically requires strongly acidic conditions and is a very 
slow process at neutral pH.  The carbonyl group and secondary amine in the amide 
structure can participate in hydrogen bonding to promote the solubilitly of the 
conjugate in protic solvents.  Amide bonding was often used when the nanoparticle 
surface contained carboxyl functions and the ligand contained a conjugable amine group 
with no competing carboxyl groups that might lead to the polymerization of the product 
unless this polymerization did not adversely affect the ligands function.  It was also 
possible to avoid polymerization by first capping the competing carboxyls with 
dihydropyran and later cleaving the cap with a dilute acid.     
 
EDC  
 1-ethyl-3-(3-dimethylaminopropyl) carbodiimide hydrochloride (EDC) forms an 
active ester leaving group called o-acylisourea with a carboxylate group.  The leaving 
group will react with an amine group to form an amide bond.  This conjugation strategy 
can be used effectively but is more appropriate when low conjugation yields are desired 
owing to inherent issues with the stability of the intermediate.  
 When using EDC as a means of conjugating ligands to surface carboxyl groups on 
nanoparticles, the nanoparticles were first dissolved at a concentration of 1-10 mg/mL 
in either distilled water, 0.1 M sodium phosphate, pH 7.4, or 0.1 M MES, pH 4.7.  The 
ligand being conjugated would then be added to the nanoparticle solution in a molar 
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excess that was varied based on the molecular weight of the ligand, the number of 
conjugable amines on the ligand, and the desired number of nanoparticle surface 
functions.  Next, an amount of EDC was added that would bring its concentration to 0.5-
0.1 M.  The resulting solution was vortexed for two hours and then the sample was 
magnetically purified, washed 3-10x with 0.1 M sodium phosphate, pH 7.4, and 
resuspended in distilled water.  Washes were always performed in PBS buffer solutions 
because the hydrogen bonding opportunities were not as prevalent as in aqueous 
solution which generally decreased the time needed to purify the sample magnetically. 
 
Sulfo-NHS and EDC 
 Sulfo-NHS and the carbodiimide EDC are both soluble in aqueous solution and 
can be used synergistically to form amide bonds more efficiently.  As mentioned, EDC 
will react with a carboxylate to form o-acylisourea as an active ester living group.  
However, the longevity of the intermediate state prior to its hydrolysis in aqueous 
solutions is brief and slow to react with target amines.  Conjugation will not take place if 
the amine cannot react with the intermediate prior to the hydrolysis event.  The 
hydroxyl group on Sulfo-NHS will quickly react with the EDC intermediate forming a 
hydrophilic reactive ester with the molecule that originally contained the carboxylate.  
This reactive ester, in turn, can expeditiously bind amine functions. 
 To conjugate ligands having primary amine functions to a nanoparticle surface 
coated with a molecule having carboxyl functions, the coated nanoparticles were 
dissolved (1 mg/mL) in a 0.1 M sodium phosphate buffer solution, pH 7.4.  The ligand 
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was then added directly to this solution.  The concentration could be based on the 
number of desired conjugates.  In the experiments that will be described later in which 
the peptide GGGGYSAYPDSVPMMSK is the ligand conjugated, the concentration used 
was 1 mg/mL.    EDC and Sulfo-NHS were then added to the solution in amounts that 
would bring their concentrations to 0.1 M and 5 mM respectively.  The solution was 
vigorously vortexed for 2 hours.  The sample was purified using a 5000 gauss magnet 
and washed 10 times with 0.1 M sodium phosphate buffer solution to remove 
unconjugated ligands and by-products.  The washed nanoparticle/ligand conjugates 
were then resuspended in distilled water.  
Aldehyde to Amine Coupling via Reductive Amination 
 An aldehyde and an amine can form a Schiff base and then be reduced to a 
stable secondary amine link using a reducing agent.  This conjugation strategy was 
effective when nanoparticles were coated with glucuronic acid, Dextran, or 
polygalacturonic acid because these molecules contained hydroxyls that could easily be 
oxidized to form reactive aldehydes using sodium periodate.  For polygalacturonic acid 
this was often a desirable alternative to having to first protect the competing carboxyl 
groups on the ligand to which it was being conjugated. 
Glucuronic Acid, Dextran, and Polygalacturonic Acid 
 Nanoparticles previously coated with glucuronic acid or a glycan could remain in 
aqueous solution or could be magnetically filtered from aqueous solution and 
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resuspended in 0.2 M sodium bicarbonate, pH 9.6.  In either case, their concentration 
was adjusted to 10 mg/mL.  A stock 0.088 M solution of sodium periodate was created 
in the dark by adding the sodium iodate to distilled water.  100 microliters/mL of the 
stock solution was added to the nanoparticle solution and allowed to react in the dark 
for 15-20 minutes.  Next, the magnetic particles were purified using a 5000 gauss 
magnetic and the filtrate was poured off.  The magnetic nanoparticles (filtrand) were 
resuspended at a concentration of 10 mg/mL in 0.2 M sodium bicarbonate, pH 9.6.  The 
ligand containing the amine was also dissolved in 0.2 M sodium bicarbonate, pH 9.6 at a 
concentration of 10 mg/mL or higher, depending on the desired number of conjugates, 
and pooled at a 1:1 ratio with the nanoparticle solution.  The combined solutions were 
given two hours to react and then 10 μL of sodium cyanoborohydride (5 M) was added 
per mL of the reaction solution.  The sodium cyanoborohydride was taken from a 5 M 
stock solution created by dissolving sodium cyanoborohydride in 5 M NaOH.  The 
reaction ran for 30 minutes while vigorously shaking.  It was essential that the work with 
sodium cyanoborohydride be performed under a fume hood owing to its high toxicity.  
Unreacted aldehydes were capped by adding 2-aminoethanol, pH 9.6 (50 μL per mL 
reaction solution) and also reacted for 30 minutes.  The final preparation was 
magnetically purified and washed 10x with 0.1 M sodium phosphate buffer to remove 
any unreacted agents and byproducts.  The sample was finally resuspended in aqueous 
solution at a concentration of 1-10 mg/mL.   
 
Chalcogen Bond Formation 
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 To synthesize the nano-triggers for the drug delivery project that will be 
described in Chapter 3 we began by activating cobalt iron ferrite nanoparticles with 
sodium hydroxide and then coating them with Dextran using the previously mentioned 
procedure.  L-selenocystine’s primary amine group was conjugated to the surface of the 
Dextran coated particle by following the reductive amination procedure previously 
described.  L-selenocystine was used because the pKa of the selenide function is 5.2 and 
would mean that the diselenide would be unstable enough at neutral pH to dissociate 
into selenate groups.   
 To synthesize the nano-carriers the selenide side of the carrier was created in 
the same manner as the nano-trigger, however once the dimer of two particles linked 
by a diselenide was isolated it was placed into a nitrogen environment where 5 mg of 
DTT was added as a reductant and allowed to incubate until needed (approximately 3 
hours later).  The DTT was used to reduce the diselenides to selenols and the nitrogen 
environment was necessary to prevent premature oxidation. 
 Although no prior studies could be found where alkyl halides were changed to 
tellurols it was assumed that the chemistry was similar to that demonstrated by 
Klayman et al.
39
 who successfully added thiol and selenide groups to alkyl halides using 
elemental sulfur and selenium combined with super hydride. 
 
NaBH4 + Se + 3C2H5OH -> NaHSe + B(OC2H5)3 + 3H2              Klayman et al. reaction 
 
NaBH4 + Te + 3C2H5OH -> NaHTe + B(OC2H5)3 + 3H2              modified reaction 
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 This was an accurate assumption and was achieved in the following manner:  2-
aminoethylbromine in HBr was produced by combining 0.9 mL of 2-aminoethanol with 
2.0 mL of HBr (a stoichiometric excess) and allowed to react for 2-3 minutes (until 
cessation of smoking and bubbling) before adding 30 mL of THF.  The solution (Solution 
A) was magnetically stirred until needed for use (approximately 2 hours later).  Solution 
A was to be mixed in a nitrogen environment with another solution and was placed 
there along with the coated MNPs before beginning the next step.  The next step 
involved the synthesis of NaHTe which was used to convert our alkyl halide to a tellurol.  
In a nitrogen environment, 2.78 mmol of grey Te was added to 5.8 mL of Li(C2H5)3BH 
(5.8 mmol).  Safety precautions were necessary owing to the combustability of the 
compound in the presence of oxygen.  A pinkish white solution formed after about 20 
minutes of magnetic stirring.  At this point 3.0 mL of THF was added and the solution 
(Solution B) was stirred for an additional 20 minutes.  Solution A and B were then 
combined and allowed to incubate with magnetic stirring for 1-2 hours.  Most of the 
solvent evaporated during mixing and we were left with roughly 8.0-9.0 mL of solution.  
1 mL of this was added to the MNPs that had been sitting in DTT and this combination 
was immediately removed from the nitrogen environment.  The objective was to oxidize 
the tellurol and selenol groups to form tellurol selenide bonds.  The oxidation process 
was facilitated by adding peroxide to the solution.  The peroxide had to be added drop-
wise with a pipette in microliter increments.  In our case, 200 microliters was sufficient.  
The solution was allowed to mix on a stir plate for one hour in open air before 
magnetically separating and washing the particles in distilled water three times.  After 
the third wash the separated particles were re-suspended in 0.1 M NaOH.  1.0 mL of 
FITC in DMSO (20 mg/mL respectively was added to the suspended particles and the 
solution was allowed to incubate overnight at 4 degrees Celsius.  In the trial involving 
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acetylsalicylic acid, FITC was supplanted by aspirin in aqueous solution.  The following 
day the particles were again magnetically separated and washed with distilled water 





 Magnetic nanoparticles have been proposed as possible vectors for targeted 
drug delivery systems.  The magnetic properities of these particles allow for a more 
controlled biodistribution.  Although the attachment of small molecules, peptides and 
other therapeutic compounds to the particle surface has been facile, the engineering of 
their controlled release has been more challenging.  In this chapter I describe the 
phased delivery of a therapeutic package using magnetic nanoparticles that are 
classified as either nano-carriers or nano-triggers.  The major difference between the 
particles is their surface modification.  For magnetic nano-carriers, the surface of the 
nanoparticle is chemically modified with certain types of linker molecules.  These linker 
molecules utilize chalcogen-chalcogen bonds to tether the particle’s cargo which may 
include various drugs, peptides or nucleic acid chains.  The nanoparticle-drug conjugate 
can be sent to a targeted region using an external magnetic field.  The surface of the 
other particle, the nano-trigger, is modified with chalcogenides.  These nano-triggers 
can exist as individual particles or as dimers bound by a chalcogen-chalcogen bond.   
Introduction 
 After translation and before its final deployment a protein must assume its 
tertiary and quaternary conformations.  Mistakes can be made during this process and 
there are biological checks and balances to insure that they are remedied.  Protein 
disulfide isomerase (PDI) is one such means of insurance.  PDI contains thiol 
functionalities that serve to break disulfide bonds that hold nascent protein structures 
together and give them another opportunity to fold correctly.  The latter example is an 
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oxidation by which two thiol hydrides pass to the sulfurs engaged in the disulfide bond.  
But once reduced, PDI can just as easily accept these hydrides back, again resulting in 
reformation of the original disulfide bond.  It was conceivable that a functional carrier 
and release mechanism could be designed using the same principal if an element of 
selectivity could be added during the cleavage process and if the exchange could take 
place at a neutral physiological pH.  Selenyl sulfide bonds seemed a logical means of 
achieving this.  Further research showed that this concept has been extensively 
employed in phase tag chemistry and studies have shown that selenyl sulfide bonds can 
be reduced more easily by thiol groups than disulfide bonds.
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  Chalcogens are also known as Oxygen Family elements and include oxygen, O; 
sulfur, S; selenium, Se; tellurium, Te; polonium, Po and ununhexium, Uuh.  The chemical 
properties of the chalcogenides were covered in Chapter 1.  It was shown that in the 
chalcogen family reductive strength is inversely proportional to atomic size and 
dichalcogenide bond strength is independent of atomic size.  This dichotomy affords 
some interesting functionality that lends well to both speed of function and selectivity 
when employed in a carry and release mechanism.  For example; a particle containing a 
thiol substituent encountering a selenyl sulfide bond will selectively exchange with the 
sulfide and free the selenol.  A free selenol will not have the reductive strength to 
replace another sulfide in a disulfide linkage and is unlikely to reattach.  The same 
scenario applies to a selenol substituent encountering a tellurol selenide bond.  The 
selenol binds to the selenide side forming a diselenide link and the tellurol side is freed.  
Kinetics studies have shown that the speed of a selenide exchange with a selenyl sulfide 
linkage is about 1.67 x 10
7
 times faster than the exchange of a thiol with a disulfide 
linkage (kinetics reference).  It was the characteristic speed and selectivity that made 
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this chemistry a viable mechanism for drug delivery and the mechanisms legitimacy was 
tested by carrying and releasing fluorescent tags and drugs donated by the NIH.    
 There was still one problem that begged revision.  Cysteine is an important 
constituent of many proteins.   The disulfide linkages formed between cysteine residues 
can be important to the maintenance of a protein’s structure.
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  It was conceivable that 
if cell membrane surface receptors or other proteins contained reduced thiol groups 
and a magnetic particle containing a selenyl sulfide linkage was introduced systemically, 
thiol/dichalcogenide exchange could take place between the selenyl sulfide bond of the 
particle and the cell membrane receptors.  If this exchange took place only at the tumor 
site when employed as a cancer drug delivery mechanism it would be of little 
consequence, save possible complications with the particle elimination post treatment.  
However, it was entirely likely that these particles would contact many non-cancer cells 
on their way to the site and any exchange there would be very undesirable.  In vitro 
tests (Figure 3.1-3.3) verified both cell surface binding and toxicity toward the cell lines 
tested.  So as stated, this issue had to be remedied.  The formation of diselenides is 
much less common than that of disulfides in vivo.  This may have to do with the 
decreased stability of the bond owing to its lower bond dissociation energy.  Although 
there was little to no information on the use of tellurol selenide linkers it seemed logical 
that incorporating them into the delivery mechanism might not only increase the speed 
of release but also preserve the selectivity.  But, more importantly, it was theorized that 




Figure 3.1:  HEY cell line prior to introducing nanoparticles with S-Se dichalcogenide 





Figure 3.2:  Agglutination of nanoparticles with S-Se dichalcogenide bonds to peptides 






Figure 3.3:  Shows rounding up of HEY cells after exposure to nanoparticles with S-Se 
dichalcogenide bonds to peptides (bright field, 10x objective). 
 
 
selenide linked carrier would not interfere with the omnipresent thiol groups in vivo.  To 
date, our research has shown that this is precisely the case. 
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  In general, the mechanism works as follows:  The first particle (Particle I) 
contains a tellurol selenide cross linkage to a package (i.e. fluorescent tag, drug, etc).  It 
is conceivable that the package or drug could be conjugated directly to the particle or 
encapsulated in a structure like a liposome and then conjugated to the particle.   The 
tellurol group is conjugated to the package side and the selenol is conjugated to the 
particle side.  The second particle (Particle II) contains selenol substituents or a 
diselenide bond between two particles.  The diselenide selenocystine was used for this 
procedure because the selenol group of selenocystine has a pKa of about 5.2 which 
would mean the diselenide would dissociate to selenates at neutral pH.  Theoretically, 
Particle I could be introduced into an organism and sequestered at a target site 
magnetically.  Particle II could be introduced to the organism sometime later where it 
would eventually arrive at the target site and also become sequestered magnetically.  A 
selenol functionality on Particle II would participate in an exchange with the tellurol 
selenide bond on Particle I forming a preferential diselenide bond with the selenium and 
liberating the tellurol group and attached package (See Figure 3.4-3.5).  The use of a 
telluride selenide bond is key to the selectivity of the mechanism.  Otherwise, as 
mentioned in the PDI scenario it is possible that the package, having a selenide group 
too, would simply reattach to another magnetic particle. 
 As a proof of concept, one group of Dextran coated nanoparticles was tagged 
with Fluorescein Isothiocyanate (FITC) using the tellurol selenide crosslinker and another 
was conjugated to the well known acetylsalicylic acid using the same linkage.  Figure 3.6 
shows the molecular structure of acetylsalicylic acid and how it was expected to be  
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X = S when Y = Se 
X = Se when Y = Te 
Figure 3.4:  Basic concept behind the dichalcogenide bonding and release mechanism 
showing how a Se-Te or S-Se bond could be used to carry and release a package 




























Figure 3.5:   Illustration of how dichalcogenide bonds and chalcogen functions can be 
used to release packages bound to magnetic nanoparticles. 
 
 
altered after its release from the magnetic nanoparticle.  The conjugation strategy used 
to form the dichalcogenide link has been described in detail in Chapter 2.  By using the 
FITC conjugate it was possible to visualize the successful formation of the bond using 
confocal microscopy (LSM 510 UV, Carl Zeiss Inc.).  Figures 3.7.A -3.7.D are confocal 




















































FITC is bound to the magnetic nanoparticle surface.   In Figure 3.7.A the bright field 
levels were raised in the photo so that it was evident that the FITC was bound to the 




Acetylsalicylic Acid Aspirin modified after release. 
Figure 3.6:  The molecular structure for acetylsalicylic acid and it’s expected altered 







Combination of bright field and dark field 
exposure at 60x.  FITC is bound to 




Dark field exposure at 60x.  Fluorescence 
confirms FITC is conjugated to MNP. 















Dark field image at 40x.  Fluorescence is 
visible throughout image indicating wide 
spread conjugation of FITC. 
Figure 3.7A-D continued 
 
 
Results and Discussion 
   In both experiments involving the conjugation of aspirin or FITC, the 
introduction of the nano-trigger, containing a diselenide, was shown to initiate release.  
The release was conducted within a chamber slide filled with distilled water.  Under 
natural light the nano-carriers were introduced to the chamber.  For the trial involving 
the FITC tagged nano-carriers, the chamber slide was placed over the objective of an 
Olympus IX70 inverted microscope.  The natural light was turned off and the epi-
flourescent (mercury arc) lamp was turned on.  The FITC tags could be seen as widely 
dispersed throughout the solution.  A magnet was placed on the side of the chamber 
and the flourescent tags were quickly pulled to that side.  Immediately, upon contact 
with other particles release began to take place.  This initial release eventually subsided 
and additional release of the FITC tags was triggered by addition of the nano-triggers 
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into the solution.  The release of the aspirin was conducted in the same manner.  
However, fluorescent microscopy was unnecessary.  The release was verified by 
analyzing the particles before and after they were agglutinated magnetically and by 
analyzing the composition of the solution once the particles were extracted.  Figure 3.8 
shows the electrospray ionization mass spectrometry (ESI-MS) data obtained from the 










Figure 3.8:  EIS-MS data for release of acetylsalicylic acid using a labile Te-Se bond. 
   
 
mass units (u).  The molecular mass of the structure containing the tellurol is 334.83 u.  
None of the peaks in the spectra appear to correspond to the expected value.  However, 
there are two prominent peaks for masses of 208.0 u and 217.1 u.  ESI-MS typically 
Scarberry sample 1
GT Mass Spectrometry Laboratory 18-Aug-2006 16:54:27






















makes use of acidic solvents that would be likely to dissolve the tellurol.  If this were the 
case then the expected mass of the complex released would be around 207.23 u which 
is very close to the mass of the peaks in the spectra. 
 As mentioned one of the initial reasons for employing the Te-Se bond was to 
avoid toxic interactions with cells in vivo.  The experiment illustrated by the results in 
Figure 3.1-3.3 was repeated with MNPs conjugated to FITC using the TeSe linkage.  The 
MNPs were incubated at 37⁰ C and an atmosphere of 5% CO2 for a period of 15 minutes 
with ovarian cancer cells (HEY, ≈2 million) that had been growing in single chamber 
slides.  After the 15 minute incubation period the cells were washed with PBS 3x and 
viewed using bright field and dark field microscopy (488 nm excitation).  Figure 3.9.A 
shows a bright field image of the HEY cells prior to incubation with the MNPs.  Figure 
3.9.B shows the HEY cells post-incubation with the MNPs and after the third PBS 
washing.  The fluorescence is positive confirmation that the MNPs were either bound to 
the cell surface or were endocytosed.  Figure 3.9.C shows the HEY cells under bright 
field, post-incubation and after the third PBS washing.  There is no visible rolling up of 
the cells in this image.   
 No extensive cytotoxicity testing was performed in the drug delivery study and 
the mechanism has yet to be tested in an animal model.  The data obtained from the 
tests that were performed support a potential novel release mechanism that is both 
selective and functional at a physiological pH.  All the preliminary tests that were 
conducted involved conjugating packages directly to the MNP using a dichalcogenide 
link.  This approach is only feasible when the package being attached contains a 
conjugation point that will not affect its function.  It was envisioned that the utility of 
the technique could be greatly expanded if the package to be conjugated was a  
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A:  HEY cells prior to 
incubation with magnetic 
nanoparticles with Se-Te 
dichalcogenide bonds to 
peptides (bright field, 10x 
objective).        . 
B:  Dark field image (460-
488 nm band-pass 
excitation filter, 10x 
objective) of HEY cells after 
incubation with 
nanoparticles with Se-Te 
dichalcogenide bonds to 
peptides.  Fluorescence is 
positive indication that 
particles have adsorbed to 
the cell membrane or have 
been endocytosed. 
C:  HEY cells after 
incubation with 
nanoparticles with Se-Te 
dichalcogenide bond to 
peptides (bright field, 10x 
objective). No “rounding 
up” was observed. 
Figure 3.9A-C:  Nanoparticles conjugated to FTIC were incubated with a cancer cell line 




liposome that could be loaded with a therapeutic molecule.  In this case the molecule 
would not need to be structurally altered.  However, this approach has yet to be tested.  
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CHAPTER 4 
TARGETING AND CAPTURING OVARIAN CANCER CELLS 





 Magnetic cobalt spinel ferrite nanoparticles coated with biocompatible 
polygalacturonic acid were functionalized with ligands specific for targeting expressed 
EphA2 receptors on ovarian cancer cells. By using such magnetic nanoparticle-peptide 
conjugates, targeting and extraction of malignant cells was achieved with a magnetic 
field. Targeting ovarian cancer cells with receptor specific peptide-modified magnetic 
nanoparticles resulted in cell capture from a flow stream in vitro and from the 
peritoneal cavity of mice in vivo. Successful removal of metastatic cancer cells from the 
abdominal cavity and circulation using magnetic nanoparticle conjugates indicates the 
feasibility of a dialysis-like treatment and may improve long-term survival rates of 
ovarian cancer patients. This approach can be applied for fighting other cancers, such as 
leukemia, once the receptors on malignant cells are identified, and the efficacy of 
targeting ligands is established. 
Introduction 
 
 Magnetic nanoparticles have promising potentials in biomedical applications 
because of the unique abilities of magnetic interactions over space and physical 
barriers.
1, 2
  Over the past several years, they have shown very promising applications as 
in vitro medical diagnostic tools. In these studies, magnetic magnetite, Fe3O4 
nanoparticles were used for ultrasensitive detection of prostate-specific antigen (PSA) 
and for detecting amyloid-β-derived diffusible ligands (ADDLs), which is a potential 
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Alzheimer’s disease (AD) marker.
6, 8
  Fe3O4 nanoparticles also have been employed in 
the in vitro detection of certain leukemia and lymphoma cells.
7, 9
 
 We have been exploring possible in vivo approaches aimed at deterrence of the 
metastatic spread of cancer cells from primary carcinomas. The lethality of cancer is 
often not due to tumorigenesis at the primary locus but due to metastasis of the 
disease. To this end, we developed biologically modified magnetic nanoparticles as part 
of a therapeutic approach to capture and extract cancer cells from the body. For cell 
capture, using nanoparticles with stronger magnetic properties than Fe3O4 would be 
required. Cobalt spinel ferrite, CoFe2O4 nanoparticles belong to the same spinel ferrite 
materials family as magnetite. However, they have displayed much stronger magnetic 
responses at ambient temperatures.
13, 43
  We chose ovarian cancer as a model to 
develop our extraction technique. Ovarian cancer is one of the most lethal gynecological 
malignancies. The survival rate for patients with late stage disease is about 20%. 
Because of the difficulty in early diagnosis of ovarian cancer, 81% of all cases are 
detected in late stages with metastatic spread of malignant cells.
44
  The most significant 
pathway of ovarian tumor spread occurs via exfoliation of malignant cells from primary 
tumor sites, leading to dissemination of cancer cells throughout the peritoneal cavity
45
 
and worsening the prognoses for cancer patients.
46, 47
  In addition, some cancer cells 
may escape during primary tumor excision, and the development of resistance in these 
cells to current chemotherapies can lead to regrowth of a tumor cell population. 
Intraoperative rupture of malignant epithelial ovarian neoplasms also has been shown 
to worsen the prognosis of patients with early stage ovarian cancer.
48
  Thus, combining 
the extraction of residual tumor cells to limit the metastatic spread as part of routine 
treatment procedures could be a strategy to improve long-term survival for cancer 
patients. 
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 We report here our study on capture of cancer cells from a flow stream in vitro 
and from the peritoneal cavity of mice in vivo using magnetic CoFe2O4 nanoparticles 
functionalized with a receptor-specific ligand. A polypeptide with a sequence of 
GGGGYSAYPDSVPMMSK was used as a targeting ligand for ovarian cancer cells. The core 
of the peptide, YSAYPDSVPMMS (YSA), was reported as an ephrin mimetic peptide that 
binds specifically to EphA2, a receptor tyrosine kinase (RTK), using the YPDSVP residues 
of the peptide sequence.
49
  Because EphA2 is more highly expressed by ovarian 
carcinoma cells when compared with normal ovarian surface epithelium,
50, 51
 magnetic 
nanoparticle−YSA peptide conjugates should be able to selectively bind to the ovarian 




Preparation of CoFe2O4 Nanoparticles with a Biocompatible Polymer Coating and with 
YSA Peptide Conjugation. 
 The superparamagnetic CoFe2O4 nanoparticles were synthesized with a micelle 
method, and the mean diameter was 8 nm with a size distribution of less than 15%. The 
detailed experimental procedures have been reported elsewhere.
13
  The nanoparticles 
(200 mg) and polygalacturonic acid (600 mg, Alfa Aesar) were added into 80 mL of 5 M 
NaOH solution at ambient temperature. After sonication for 5 h with a Model 60 Sonic 
Dismembrator (Fisher Scientific), the coated nanoparticles were separated from the 
solution using a magnet. After being washed a few times with water, the coated 
nanoparticles were resuspended in distilled water. Glucuronic acid was also tested as 
the biocompatible coating with similar procedures. 1.9 mg of peptide having a sequence 
of GGGGYSAYPDSVPMMSK were added to 10 mL of an aqueous suspension of the 
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nanoparticles with polygalacturonic acid coating (~1.7 × 1015 particles/mL). The mixture 
was sonicated for a few minutes. The solution was protected from light and stored at 4 
°C overnight to complete the formation of amide bonds between carboxyl groups on the 
polymer coating and the primary amine on the C-terminal lysine residue. 
 The YSA peptide was synthesized using standard Fmoc chemistry as reported in 
the literature.
52
  A Rhodamine tag was conjugated on the N-terminus, and the four N-
terminal glycine residues were used to distance the Rhodamine from the binding region 
and prevent steric hindrance to receptor binding. 
 
Cell Growth. 
 The BG-1 cell line was provided by Julie M. Hall and Kenneth S. Korach of the 
Environmental Disease and Medicine Program, Research Triangle Park, NC. The BG-1 
cells were cultured in DMEM:F12/50:50 (Invitrogen) supplemented with 10% heat-
inactivated fetal bovine serum (FBS) (Invitrogen), 100 U/mL penicillin, and 100 μg/mL 
streptomycin (Mediatech, Inc., Herndon, VA) at 37 °C, in a 5% CO2 atmosphere. The Hey 
cell line was provided by Gordon Mills, Department of Molecular Therapeutics, The 
University of Texas, MD Anderson Cancer Center. The Hey cells were propagated in 
RPMI 1640 (Mediatech) supplemented with 2 mM of L-glutamine (Sigma), penicillin, 
streptomycin, and 10% heat-inactivated FBS at 37 °C, in a 5% CO2 atmosphere. 
 
Cell Staining.  
Cells were incubated overnight with 20 mg/mL of fluorescein diacetate (FDA) 
(Research Organics) or 20 mg/mL 5(6)-carboxyeosin diacetate (Research Organics) at 37 
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°C, 5% CO2. Cells were removed from the cell culture flask with trypsin+EDTA, washed 
once with PBS, and resuspended to 2.8 × 10
6 
cells/mL. For confocal imaging, cells were 
incubated overnight on chamber slides (Laboratory Tek) and washed the next day with 
PBS. Rhodamine labeled nanoparticles with or without conjugated YSA peptide were 
added to the cells and incubated for 1 h at 37 °C, in a 5% CO2 atmosphere. Cells were 
washed followed by fixation in 4% paraformaldehyde and coverslipped for imaging 
analysis. 
 
Mouse Studies.  
Female nu/nu mice were obtained from Taconic (Hudson, NY) and Balb/c mice 
were from Harlan (Indianapolis, IN). All experiments were conducted with the approval 
of the Institutional Animal Care and Use Committee at the Georgia Institute of 
Technology (Atlanta, GA). 
 
Microscopy.  
In vitro studies were conducted using a 40× objective on an Olympus IX71 
inverted microscope with green and red filters and a mercury short arc HBO lamp. 
Images and video were taken using an Olympus DP71 12.5 million pixel digital camera. 
Confocal images were obtained with a 40× objective using a Zeiss LSM 510 laser 
scanning confocal microscope. 
 
Results and Discussion 
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The magnetic CoFe2O4 nanoparticles were coated with biocompatible 
polygalacturonic acid to diminish the adverse immune response
18
  and also to facilitate 
the surface modification. After coating of the polymer, the particles became irregular in 
shape and with a dimension in the range 100−200 nm.  Glucuronic acid also worked very 
well as a biocompatible coating, which formed a shell around each nanoparticle with a 
thickness of 5−10 nm. 
Hey and BG-1 ovarian carcinoma cell lines were used in our studies. While both 
Hey and BG-1 lines showed expression of EphA2, the expression was several fold higher 




Figure 4.1:  Expression of EphA2 receptor in the Hey and BG-1 cell lines. (a) Immunoblot 
demonstrating the low expression of EphA2 by the BG-1 cell line and the high expression 
of the receptor in the Hey cell line. β-Actin was used to show equal loading of the  




 in vitro, these cancer cell lines were incubated with fluorescein diacetate (FDA) (Figure 
4.1.B) with the green emission at 515 nm, which can be distinguished from the 
nanoparticulate conjugates with the Rhodamine tag emitting red at 610 nm. The labeled  
Hey cells were introduced into a circulating system driven by a peristaltic pump to 
determine if EphA2 expressing cells could be extracted from a flow stream. A capillary 
tube, with a flow rate of ~1.22 mL/min inside, was centered in the circuit and placed 
above a microscope objective. The continual flow of the green fluorescent Hey cells was 
observed through the tube. Approximately 2 min after the introduction of Rhodamine-
tagged magnetic nanoparticle−YSA peptide conjugates, a magnet, with a field strength 
of ~2600 gauss, was placed on one side of the capillary tube, and the Hey cells 
accumulated on the tube wall closest to the magnet. When the magnet was removed, 
the accumulated Hey cell aggregates dispersed rapidly back into the circulating stream. 
The cells did not show any response to the magnet if the same magnetic nanoparticles 
were used but without the YSA peptide ligand. The capture of the cancer cells by the 
magnet demonstrated the peptide-functionalized nanoparticles caused the cells to 
become magnetically attractable. Therefore, it may be feasible to effectively remove 
disseminated cancer cells from the circulation or peritoneal cavity using a dialysis-based 
approach. 
 
The specific binding of the YSA-conjugated magnetic nanoparticles to Hey cells 
was verified by using confocal microscopy studies. Hey cells were incubated in chamber 
slides and allowed to adhere to the slides overnight. The next day, cells were washed 
and incubated with Rhodamine-tagged magnetic nanoparticles or with the conjugates of 
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the Rhodamine-tagged magnetic nanoparticle and YSA peptide. Cells were then fixed, 
and the binding of the magnetic nanoparticles to the cells was examined under 
fluorescence. Cells incubated with Rhodamine-tagged nanoparticles showed little or no 
binding to the particles (Figure 4.2.A) while cells incubated with Rhodamine-tagged 
nanoparticle−YSA peptide conjugates showed binding of the particles over a large 
amount of the cell surface area (Figure 4.2.B). A higher magnification of one of the Hey 
cells with Rhodamine-tagged nanoparticle−YSA peptide conjugates is shown in Figure 
4.2.C.  This result indicates that the magnetic nanoparticles bind specifically to the Hey 
cells through the YSA peptide/EphA2 interaction and that nonspecific binding of non-









Figure 4.2.  Confocal microscopic images (bright field and fluorescent overlays) of in 
vitro targeting of Hey cells. (a) Hey cells incubated with Rhodamine-tagged magnetic 
nanoparticles with no peptide conjugate (200X). (b) Hey cells incubated with 
Rhodamine-tagged nanoparticle−YSA peptide conjugates (200×). (c) Higher 




For testing cell capture in vivo, approximately 1.4 × 10
6
 FDA-loaded Hey cells in 
500 μL of PBS were introduced by injection into the peritoneum of an anesthetized 
female nu/nu mouse and allowed to disperse for 5 min with gentle abdominal massage 
to facilitate cell diffusion. The abdomens of the mice were exposed to 488 nm light 
under a stereo microscope, and there was no visible fluorescent signal at or around the 
injection site. This was followed by the injection of 500 μL of Rhodamine-tagged 
magnetic nanoparticle−YSA peptide conjugates. After an additional 5 min of incubation 
with abdominal massage, the abdomens of the mice were examined under the 
microscope and no visible fluorescent signal was observed. After a 2600 gauss magnet 
with a size of ~1 cm
3
 was placed on the skin of the abdomen for 30 s and then removed, 
the mouse was exposed to 488 nm light again (Figure 4.3.A). A green emission from the 
FDA-loaded Hey cells was clearly visible through the skin at the site of magnet 
placement (Figure 4.3.A and 4.3.B), which indicated a large accumulation of Hey cells at 
this site. When the excitation wavelength was switched to 530 nm to excite the 
Rhodamine tag, a red emission was visible through the skin at the same spot indicating 
the existence of Rhodamine-tagged nanoparticulate conjugates (Figure 4.3.C), which 
was consistent with the presence of the dark mass under the bright field (Figure 4.3.D). 
When the magnet was moved over the region and then pulled about 1 cm away from 
the original aggregation site, the green and red fluorescent spots shifted to the new 
location. The lack of any visible fluorescent signal prior to applying a magnet onto the 
mice suggested the dispersion of cells and nanoconjugates. The results obtained with a 





 Figure 4.3:  In vivo peritoneal targeting of Hey and BG
conjugates. (a) Green fluorescence of FDA
abdominal skin of an anesthetized mouse. The cells were pulled to the cavity surface by the magnet via 
the nanoparticulate conjugates. (b) Close view of the FDA
skin at the site of the magnet. (c) The nanoparticulate conjugates emitting red through the skin at the site 
of the Hey cells shown in image b. (d) Magnetic nanoparticle
the peritoneum under a bright field at the site of the magnet. (e) No visible fluorescence of FDA
BG-1 cells through the abdominal skin of an anesthetized mouse under the illumination after the magnet 
was removed. (f) Close view of the green fluorescing BG
The nanoparticulate conjugates emitting red at the site of the BG
nanoparticle−YSA peptide conjugates observed under a bright fiel
were taken using a Canon C5050Z digital camera on an Olympus SZX12 stereo microscope with green and 










-1 cells with magnetic nanoparticle
-loaded Hey cells in the center of illumination through the 
-loaded Hey cells emitting green through the 
−YSA peptide conjugates observed through 
-1 cells after the abdominal skin was removed. (g) 
-1 cells shown in image f. (h) Magnetic 








-1 cells. Images 
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nanoparticulate conjugates in the peritoneal cavity of the mouse via YSA peptide/EphA2 
recognition and then were consolidated onto the topside of the cavity by the magnet. 
The same study was conducted on FDA-loaded BG-1 ovarian cells. Although the 
fluorescence of BG-1 cells in vitro was as intense as that of the Hey cells, no visible 
fluorescent emission through the skin was observed upon exposure of the abdomen of 
the mouse to the 488 nm excitation light (Figure 4.3.E). Fluorescence was visible 
through the peritoneum once the outer abdominal skin was removed (Figure 4.3.F). The 
emission was much weaker compared to the one produced by the same number of Hey 
cells. Intense red fluorescence was clearly seen when the excitation wavelength was 
switched to the 530 nm range (Figure 4.3.G), and the nanoparticles were easily seen 
under a bright field (Figure 4.3.H). This indicated that the lack of BG-1 cell aggregates 
was not due to a shortage of Rhodamine-tagged magnetic particle conjugates. Thus, the 
low intensity of the fluorescent emissions from the BG-1 cells could be attributed to a 
smaller number of cells being sequestered by the nanoparticulate conjugates because of 
relatively low EphA2 receptor expression by the BG-1 cell line. A total of four trials were 
run for each cell line producing similar results. 
The difference in extraction efficiencies of the Hey and BG-1 cells implies the 
specificity of YSA peptide, which was confirmed by in vivo experiments on magnetic 
extraction of a mixed population of Hey and BG-1 cells within the peritoneal cavity. The 
Hey cells were incubated with FDA, and the BG-1 cells were incubated with 5(6)-
Carboxyeosin diacetate (CDA) with a 560 nm emission. An equal number of cells from 
each cell line was mixed and introduced into the peritoneal cavity of three Balb/c female 
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mice. After 5 min of cell incubation and abdominal massage, magnetic nanoparticulate 
conjugates were injected into the peritoneal cavity and incubated for 5 min. The 
peritoneal fluid was extracted and filtered magnetically before being examined using a 
hemocytometer to determine the number of green fluorescent (Hey) and red 
fluorescent (BG-1) cells. Although the initially mixed cell populations contained 50% Hey 
and 50% BG-1 cells, Hey cells accounted for 95−100% of extracted cell populations on 
average from the three trials (Figure 4.4). The scarcity of BG-1 cells in extracted cell 
populations was consistent with the specificity of YSA peptide−magnetic 
nanoconjugates. The highly specific binding of the YSA peptide to the EphA2 receptor 
enabled the magnetic conjugates to differentiate EphA2-rich ovarian carcinoma cells 
from EphA2-poor cells. 
 
 
Figure 4.4:   Extraction efficiencies of the Hey and BG-1 cells. Compositions of Hey and 
BG-1 cells in the cell populations extracted from the peritoneum of three Balb/C female 
mice. The ratios were averaged from five counts performed on each of three mice. Error 
bars show the standard deviations. 
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 Our initial findings demonstrate that magnetic nanoparticle−YSA peptide 
conjugates can target and remove metastatic cancer cells from the fluid of the 
abdominal cavity or circulatory system. Such results suggest the feasibility of a dialysis-
like system for the extraction of cancer cells, which, combined with surgery and 
chemotherapy, may improve the long-term survival rates for cancer patients. In ovarian 
cancer cases, significant removal of disseminated cancer cells from the abdominal cavity 
could lead to reduction of the malignant cell population and reduce the odds of 
metastatic spread. Additional studies, including evaluation of toxic effects from 
magnetic nanoparticles, are needed before this method can advance to clinic trial stage. 
Further improvement of this concept may include refinement of the extraction process 
with an array of peptides using patient specific tumor protein expression profiles. Since 
small peptides have been reported to prevent tumor cell adherence onto tissues in a 
murine model using a bladder tumor cell line,
53
 they might also be incorporated into the 
magnetic cell extraction technique to reduce the possibility of tumor implants and 
therefore greatly enhance the efficiency of preventing metastatic spread of cancer. 
Since EphA2 is also highly expressed in other types of cancers, applications of the YSA 
peptide−magnetic nanoconjugates could be expanded beyond ovarian cancers. 
Furthermore, this in vivo extraction approach utilizing magnetic nanoparticles may also 
be used in principle for the treatment of viral diseases by targeting and removing viruses 
and virus-infected cells and therefore bolster the immune system to fight infections. 
Next Steps 
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 The work described in this study has been expanded to include additional 
studies.  The Ascites Study is a study to determine whether magnetic nanoparticles 
conjugated to YSA peptides can capture human ovarian cancer cell lines resident in 
ascites fluid collected from ovarian cancer patients.  The Ovarian Cancer Survival Study 
is a study testing the efficacy of the technology at improving longevity using a 
metastatic ovarian cancer mouse model.  Both studies are discussed in detail in 
Chapters 5 and 6 respectively.  
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CHAPTER 5 
ISOLATION OF OVARIAN CANCER CELLS FROM THE PERITONEAL (ASCITES) 
FLUID OF OVARIAN CANCER PATIENTS USING SUPERPARAMAGNETIC 
COBALT SPINEL FERRITE NANOPARTICLES WITH PEPTIDE CONJUGATES 
 
 Serous effusions from patients with late stage (III, IV) ovarian carcinoma contain 
adenocarcinoma cells with metastatic potential.  Selective removal of these cells from 
serous fluids could abate metastases and increase 5 year survival rates.  We have 
previously demonstrated that superparamagnetic nanoparticles conjugated to a 
mimetic peptide with high affinity for EphA2, a receptor expressed on the surface of 
ovarian cancer cells, can be used to harvest these cells from the abdomen of 
experimental mice. In this study, we demonstrate that these nanoparticles can be used 
to successfully isolate free floating ovarian cancer cells from peritoneal (ascites) fluid 
collected from human ovarian cancer patients. Our results demonstrate the potential -
clinical significance of our methodology in the treatment of ovarian cancer. 
 
Introduction 
Carcinoma of the ovaries frequently results in the accumulation of fluids in the 
peritoneal and pleural cavities. 
54
 Lymphatic obstruction and over-production of 
peritoneal fluids by the epithelial cells of the peritoneal cavity are responsible for the 
bulk of the fluid accumulation.
55, 56
  The constituents of these effusions include 
malignant cells exfoliated from the primary tumor as well as dendritic and other 
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immunological cell types.  Previous studies have shown that the presence of immune 
cells in the peritoneal cavity of ovarian cancer patients is seldom sufficient to prevent 
the expansion of carcinomas.  Cancer cells generate factors
57, 58
 that prevent the 
requisite maturation required for dendritic cells to present tumor antigens and mount 
an effectual anti-tumor response.
59, 60
  For this reason, alternative strategies are 
required to help abate the metastatic potential of free floating cancer cells in the 
peritoneal fluid of ovarian cancer patients.   
The lethality of ovarian cancer is partially credited to its being relatively 
asymptomatic in the early stages and its rapid metastatic spread intraperitoneally.  The 
presence of malignant cells in accumulated ascites is often indicative of a poor prognosis 
for the majority of patients.
61, 62
  The dangers associated with leaving the malignant cells 
unabated are almost unquestionably mortal.  Unhindered malignant cells with 
metastatic potential can establish tumor sites at foci distant to the primary tumor locus 
and result in an untreatable expansion of the disease.  The 5-year survival rates of 




Immunochemical methods have been extensively applied to selectively identify 
carcinomas in peritoneal effusions.  Various studies have identified antigens with high 
expression profiles in malignant ovarian cancer cells.  The antibody to the human 
epithelial antigen (HEA), Ber-EP4 
64, 65
 , the extracellular domain of the MUC16 cell 
surface protein, CA125 
66-69
, and a receptor tyrosine kinase (RTK), EphA2 
70
,  have been 
determined to be highly selective markers for free floating ovarian cancer cells.  These 
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markers are currently being leveraged by various targeted modalities to avoid the 
collateral damage associated with the less discriminate radiation and chemo 
therapies.
71, 72
  Our previous studies have indicated the potential viability of reducing 
metastatic implantation and increasing 5-year survival rates of ovarian cancer patients 
by reducing the titer of malignant cells in peritoneal or other serous effusions.
42
  We 
have previously shown that a peptide mimetic of ephrin with high affinity for the EphA2 
receptor can be conjugated to superparamagnetic nanoparticles for targeted extraction 
of  ovarian cancer cells from the  peritonea of experimental mice. We demonstrate here 
the potential clinical significance of this methodology by in vitro isolation of ovarian 
cancer cells from human ascites fluids.  
Materials and Methods 
 
Nanoparticle Synthesis. 
The superparamagnetic CoFe2O4 nanoparticles were synthesized with a 
microemulsion technique and the mean diameter was 8 nm with a size distribution of 
less than 15%. The detailed experimental procedures have been reported elsewhere.
13
   
 
Nanoparticle Coating and Peptide Conjugation. 
 600 mg of CoFe2O4 nanoparticles were added to 300 mL of 5M NaOH and 
sonicated for 10 min (Fisher Dismembrator 60 – power setting of 19).  1800 mg of 
glucuronic acid was added to the solution and sonication continued for 1.5 hours.  The 
product was magnetically separated using a 5000 gauss magnet, washed 3x in PBS and 
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resuspended in 600 mL of distilled H2O  bringing the nanoparticle concentration to 
approximately 1 mg/mL.  Particles used in control studies were taken from this stock 
solution.  To add peptide conjugates, the nanoparticles coated with glucuronic acid 
were magnetically filtered from 300 mL of the stock solution and resuspended in 30 mL 
of 0.2 M sodium bicarbonate, pH 9.6.  3 mL from a solution of 0.088 M sodium 
periodate was added and allowed to react in the dark for 20 minutes.  The nanoparticles 
were again magnetically filtered from solution using a 5000 gauss magnet and 
resuspended in 30 mL of 0.2 M sodium bicarbonate, pH 9.6.  60 mg of the N-terminally 
Rhodamine-conjugated peptide GGGGYSAYPDSVPMMSK (2127.9 g/mol) was dissolved 
in 6 mL of 0.2 M sodium bicarbonate, pH 9.6, and then pooled with the 30 mL 
nanoparticle solution.  The reaction was allowed to proceed on a platform shaker at 
room temperature and in reduced light for two hours.  360 µL of sodium 
cyanoborohydride (5 M) was added to the solution in a fume hood and the reaction 
proceeded for an additional 30 minutes under the same conditions.  1.8 mL of 2-
aminoethanol was then added to cap unreacted aldehydes and the reaction proceeded 
for an additional 30 minutes.  The final product was magnetically separated from the 
solution using a 5000 gauss magnet and washed 10x with 0.1 M sodium phosphate 
buffer and then resuspended in 300 mL of distilled H2O.  The average diameter of the 
nanoparticle (approximately 8 nm), the density of the particle (5.29 g/mL), and the mass 
of the peptide (2127.9 Da) were used to calculate an approximate peptide to particle 




The GGGGYSAYPDSVPMMSK peptide was synthesized using standard Fmoc 
chemistry.
52
  A Rhodamine tag was conjugated on the N-terminus, and the four N-
terminal glycine residues were used to distance the Rhodamine from the binding region 
and prevent steric hindrance of EphA2 receptor binding. 
 
Ascites Fluid Preparation. 
Ascites samples were obtained from the Ovarian Cancer Institute of Atlanta, 
Georgia.  Collection methods have been well documented.
73
  Ascites samples were 
stored at -80⁰ C in 10% DMSO and thawed in a 37⁰C water bath in preparation for use. 
 
Cell Extraction. 
For each sample being tested five 12 x 75 mm round-bottom tubes were labeled 
as follows:  Tube 1 – pure ascites, Tube 2 – filtrand, Tube 3 – filtrate, Tube 4 – filtrand 
control, Tube 5 – filtrate control.  500 µL of ascites fluid was added to Tube 1, 2 and 4.  
700 µL of ice cold PBS (10% FBS, 1% sodium azide) was added to Tube 1 and it was 
stored on ice for analysis.  200 µL of peptide conjugated magnetic nanoparticles (1 
mg/mL) and 500 µL of ice cold PBS (10% FBS, 1% sodium azide) were added to Tube 2.  
Tube 2 was vortexed for 15 seconds and shaken for 10 minutes by hand.  Tube 2 was 
then attached to a 5000 gauss magnet for 10 minutes.  With the magnet attached to the 
tube, the fluid was pipetted from Tube 2, placed in Tube 3, and Tube 3 was stored on ice 
for analysis.  The captured magnetic nanoparticles were washed in sterile PBS 3x and 
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resuspended in 300 µL of same.  The 300 µL nanoparticle solution was filtered through 
the cap of a 12 x 75 mm round-bottom tube, the volume was raised to 1200 µL using 
sterile PBS, and Tube 2 was stored on ice for analysis.  200 µL of magnetic nanoparticles 
having no peptide conjugate (1 mg/mL) and 500 µL of ice cold PBS (10% FBS, 1% sodium 
azide) were added to Tube 4.  Tube 4 was vortexed 15 seconds, shaken for 10 minutes 
by hand, and then attached to a 5000 gauss magnet for 10 minutes.  While attached to 
the magnet, the fluid was pipetted from Tube 4, placed in Tube 5, and Tube 5 was 
stored on ice for analysis.  The captured magnetic nanoparticles were washed in sterile 
PBS 3x and resuspended in 300 µL of same.  The 300 µL nanoparticle solution was 
filtered through the cap of a 12 x 75 mm round-bottom tube, the volume was raised to 
1200 µL using sterile PBS, and Tube 4 was stored on ice for analysis.  Tubes 1-5 were 
analyzed immediately using a BD LSR flow cytometer (BD Biosciences).     
  
Cell Surface Staining. 
300 µL of ascites fluid was resuspended in 12 x 75 mm round-bottom tubes 
containing 500 µL of ice cold PBS (10% FBS, 1% sodium azide).   All manipulations 
involving fluorophore-conjugated antibodies were performed in the dark.   The samples 
were centrifuged at 800 RPM and 4⁰ C for 5 minutes and the supernatant volume was 
reduced to the 300 µL mark at the base of the tube.  100 µL of ice cold PBS (10% FBS, 1% 
sodium azide) was added to the sample and the tube was gently agitated to re-suspend 
the cells.  10 µL of the primary antibody was added and the sample was left to incubate 
on ice for 30 min.  500 µL of ice cold PBS (10% FBS, 1% sodium azide) was added to each 
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sample and the samples were centrifuged at 800 RPM and 4⁰ C for 5 minutes.  DIRECT 
STAINING –The previous washing step was performed 3 times and the cells were 
resuspended in 1200 µL of ice cold PBS (10% FBS, 1% sodium azide) and analyzed 
immediately using a BD LSR flow cytometer (BD Biosciences). INDIRECT STAINING –The 
washing step was performed 3 times and the cells were resuspended in 100 µL of ice 
cold PBS (10% FBS, 1% sodium azide).  10 µL of the secondary antibody was added and 
the sample was left to incubate on ice for 30 min.  500 µL of ice cold PBS (10% FBS, 1% 
sodium azide) was added to each sample and the samples were centrifuged at 800 RPM 
and 4⁰ C for 5 minutes.  This washing step was performed 3 times and the cells were 
resuspended in 1200 µL of ice cold PBS (10% FBS, 1% sodium azide) and analyzed 
immediately using a BD LSR flow cytometer (BD Biosciences).     
 
Flow Cytometry. 
For each sample analysis using the BD LSR flow cytometer (BD Biosciences) the 
software configurations (BD Facs/Diva, BD Biosciences) remained consistent.  Forward 
(FSC) and side scatter (SSC) patterns were recorded with a four decade log amplifier.  
The threshold was set to 2000 and the voltages for the FSC, SSC, FITC, and PE-A 
parameters were set to 505, 236, 500, and 401 respectively.  For each trial 10,000 
events were recorded.  Gating of populations was established for a particular patient 
sample and copied to successive trials to preserve statistical viability.       
 
Flourescence Microscopy.  
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100 µL of the solutions from each tube used for flow cytometry analysis was 
added to a falcon tube along with 10 µL of Trypan Blue and a small volume was plated 
for viewing.  A 2500 gauss magnet was used to aggregate the magnetic nanoparticles in 
the solutions from Tube 2 and the aggregate and fluid were placed on a microscope 
slide for viewing (Olympus X51 Inverted Flourescence Microscope) and imaging 




Flow cytometry has been successfully employed in other studies to differentiate 
the cell populations resident in peritoneal and pleural effusions.
74
  In the described 
study we employed flow cytometry to analyze pure ascites samples, the filtrand 
removed from these samples using peptide-conjugated and non-peptide-conjugated 
superparamagnetic nanoparticles, and the filtrate remaining in the sample after the 
filtrand was removed.  Bivariate analysis was used to establish significant variation 
between the number of cells extracted using peptide-conjugated nanoparticles and the 
number extracted using nanoparticles with no peptide conjugate.  Immunophenotyping 
techniques were used to verify whether the cells being extracted resided in populations 
testing positive for markers associated with ovarian adenocarcinoma cells or antigen 
presenting cells that might be displaying these markers.   
 
Identifying Extracted Cell Populations. 
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 A baseline of resident cell populations in ascites samples was determined 
by observing bivariate displays of forward and side scatter patterns produced when the 
untreated samples were analyzed using a BD LSR flow cytometer (BD Biosciences).  Dot 
plots for 3 separate trials conducted on patient samples 914 and 923 are featured in 








Figure 5.1:  Dot plots for flow cytometry analysis (Trials 1-3) of untreated ascites sample 









Figure 5.2:  Dot plots for flow cytometry analysis (Trials 1-3) of untreated ascites sample 




display morphological consistency across each trial.  Quantitative confirmation of this 
consistency was obtained by gating the visually discreet populations on a density plot of 




Figure 5.3:  Density plot of flow cytometry analysis of ascites sample for patient 914 





Figure 5.4:  Density plot of flow cytometry analysis of ascites sample for patient 923 




successive trial, and displaying the percent of total recorded events (% Total) for each 
gated population (Figures 5.5.A-C and 5.6.A-C).  The three trial average % Total for each 









Figure 5.5:  Density plot of flow cytometry analysis of ascites samples for patient 914 




Table 5.1:  % Total for each population gated on density plots obtained from flow 
cytometry analysis of the untreated ascites samples of patient 914 (Averaged for Trials 
1-3). 
POPULATION AVERAGE (TRIALS 1-3) STD DEVIATION (TRIALS 1-3) 
1 15.70 2.66 
2 58.86 2.35 
3 7.28 0.46 











Figure 5.6:  Density plot of flow cytometry analysis of ascites samples for patient 923 




Table 5.2:  % Total for each population gated on density plots obtained from flow 
cytometry analysis of the untreated ascites samples of patient 923 (Averaged for Trials 
1-3). 
POPULATION AVERAGE (TRIALS 1-3) STD DEVIATION (TRIALS 1-3) 
1 11.02 0.21 
2 61.32 1.17 
3 3.65 0.22 
4 4.70 0.35 
 
 
 Superparamagnetic CoFe2O4 nanoparticles (200 µL – 1 mg/mL) coated with 
glucuronic acid and having N-terminally Rhodamine-conjugated 17 residue peptide 
functions (GGGGYSAYPDSVPMMSK) were added to 1.0 mL peritoneal effusion samples 
diluted in sterile PBS (dilution factor 1:2) and given 10 minutes to incubate at ambient 
temperature.  The superparamagnetic nanoparticle conjugates (filtrand) were 
magnetically filtered from the samples during a 10 minute exposure to a 5000 gauss 
magnet.  The filtrand was washed 3x with sterile PBS, resuspended in 300 µL of same, 
and filtered through a 12 x 75 mm falcon tube cap at 800 RPM (4⁰ C) for 5 minutes.  The 
volume of the filtrand sample was increased to 1200 µL.  The filtrate remaining from the 
extraction was added to a 12 x 75 mm falcon tube.  The filtrand and filtrate were 
analyzed using the BD LSR flow cytometer (BD Biosciences) (Figures 5.7.A-C, 5.8.A-C, 
5.9.A-C, and 5.10.A-C).  The morphologies of the dot plots featured in Figures 5.7 and 
5.8 are dissimilar to the dot plots in Figures 5.1 and 5.2.  The gates from the untreated 
ascites trial for each patient were superimposed over the dot plots obtained from the 
filtrand and filtrate samples to determine the % Total delta for each population (Figures 
























by aggregates of the coated magnetic nanoparticles alone, 200 µL of the glucuronic acid-
coated nanoparticles with and without peptide conjugates were added to separate 12 x 
75 mm Falcon tubes containing 1.0 mL sterile PBS and the samples were analyzed using 
the BD LSR flow cytometer (BD Biosciences) (Figure 5.15.A-F, Table 5.7).  The bivariate 
plot produced by the nanoparticles was gated and the gates for populations 2 and 3 of 






















was repeated three times on each patient sample and then conducted three more times 
using glucuronic acid coated superparamagnetic nanoparticles with no peptide 
conjugates (Figures 5.16.A-C, 5.17.A-C, 5.18.A-C, and 5.19.A-C).      
Visual inspection of the plots of FSC versus SSC for each patient’s untreated 









Figure 5.11:  Dot plot of flow cytometry analysis of filtrand samples for patient 914 
(Trials 1-3) showing gates copied from untreated ascites trial (Trial 1), frequencies, and 
population labels (1-4). 
 
 
Table 5.3:  % Total for each population gated on dot plots obtained from flow cytometry 
analysis of the filtrand samples of patient 914 (Averaged for Trials 1-3). 
POPULATION AVERAGE (TRIALS 1-3) STD DEVIATION (TRIALS 1-3) 
1 0.88 0.19 
2 10.58 1.61 
3 6.54 1.44 





by gates P1 and P2 initially held the largest average number of events (Tables 5.1 and 
5.2).  The average % Total values for each population from the filtrand and filtrand 
control trials are featured in Tables 5.3, 5.4, 5.8, and 5.9.  An average of 5.60% +/- 1.54% 
(mean +/- standard deviation), 17.97% +/- 2.81%, 89.84% +/- 20.58%, and 4.81% +/- 
0.56% of the cells in the ascites samples from patient 914 were extracted using peptide 
conjugated nanoparticles from populations P1, P2, P3 and P4 respectively (See 
Calculation 1) while 0.19% +/- 0.13%, 0.46% +/- 0.19%, 4.53% +/- 0.74 %, and 0.27% +/- 
0.27% were extracted using nanoparticles with no peptide conjugates from the same 
respective gated populations.  For patient 923 samples an average of 13.70% +/- 1.0%, 
20.92% +/- 2.24%, 32.05% +/- 2.37%, and 2.13% +/- 0.87% of cells were extracted using 
peptide conjugated nanoparticles and 2.45% +/- 0.64%, 5.02% +/- 0.45%, 6.58% +/- 
0.91%, and 0.00% of cells were extracted using nanoparticles with no peptide 
conjugates from populations P1, P2, P3, and P4 respectively. 
 
CALCULATION 1:  Sample calculation used to determine the percentage of cells extracted from a gated 
population.  It was determined that an average of 5.60% +/- 1.54% (mean + standard deviation) of the 
cells was extracted from population P1 of ascites samples taken from patient 914 using the following 
data: 
 
The average % Total of gate P1 for three untreated ascites samples was 15.70% +/- 2.66%. 
The average % Total of gate P1 for three filtrand trials was 0.88% +/- 0.19%. 
 
y = 0.88      бy = 0.19 
t = 15.70     бt = 2.66 
g = y/t     g = 0.88 / 15.70 = 0.0560  or 5.60% 
 
Error propagation: 









Figure 5.12:  Dot plot of flow cytometry analysis of filtrand samples for patient 923 
(Trials 1-3) showing gates copied from untreated ascites trial (Trial 1), frequencies, and 
population labels (1-4). 
 
 
Table 5.4:  % Total for each population gated on dot plots obtained from flow cytometry 
analysis of the filtrand samples of patient 923 (Averaged for Trials 1-3). 
POPULATION AVERAGE (TRIALS 1-3) STD DEVIATION (TRIALS 1-3) 
1 1.51 0.11 
2 12.83 1.35 
3 1.17 0.05 









Figure 5.13:  Dot plot of flow cytometry analysis of filtrate samples for patient 914 
(Trials 1-3) showing gates copied from untreated ascites trial (Trial 1), frequencies, and 




Table 5.5:  % Total for each population gated on dot plots obtained from flow cytometry 
analysis of the filtrate samples of patient 914 (Averaged for Trials 1-3). 
POPULATION AVERAGE (TRIALS 1-3) STD DEVIATION (TRIALS 1-3) 
1 9.74 1.16 
2 62.30 1.81 
3 4.00 0.54 











Figure 5.14:  Dot plot of flow cytometry analysis of filtrate samples for patient 923 
(Trials 1-3) showing gates copied from untreated ascites trial (Trial 1), frequencies, and 
population labels (1-4). 
 
 
Table 5.6:  % Total for each population gated on dot plots obtained from flow cytometry 
analysis of the filtrate samples of patient 923 (Averaged for Trials 1-3). 
POPULATION AVERAGE (TRIALS 1-3) STD DEVIATION (TRIALS 1-3) 
1 11.90 0.36 
2 65.13 0.38 
3 3.24 1.16 











Figure 5.15:     A:  Dot plot of flow cytometry analysis of superparamagnetic 
nanoparticles coated with glucuronic acid and peptide functions B-C:  Dot plot of flow 
cytometry analysis of superparamagnetic nanoparticles coated with glucuronic acid and 
peptide functions showing gates copied from untreated ascites trial (Trial 1) for patient 
sample 914(5.15.B) and 923(5.15.C).  D:  Dot plot of flow cytometry analysis of 
superparamagnetic nanoparticles coated with glucuronic acid and no peptide functions 
E-F:   Dot plot of flow cytometry analysis of superparamagnetic nanoparticles coated 
with glucuronic acid and no peptide functions showing gates copied from untreated 





Figure 5.15 continued 
 
Table 5.7:  % Total for each population gated on dot plots obtained from flow cytometry 
analysis of the superparamagnetic nanoparticles coated with glucuronic acid and 





















1 0.81 0.11 0.77 0.09 
2 1.35 1.07 3.92 4.33 
3 0.00 0.00 0.00 0.00 


















Figure 5.16:  Filtrand extracted from patient samples (Patient 914) using nanoparticles 










Figure 5.17:  Filtrand extracted from patient samples (Patient 923) using nanoparticles 























Figure 5.18:  Filtrand extracted from patient samples (Patient 914) using nanoparticles 
having no peptide conjugates.  Population gates were copied from previous trials 
performed on untreated ascites and pure nanoparticle samples. 
 
 
Table 5.8:  % Total for each population gated on dot plots obtained from flow cytometry 
analysis of the filtrand control samples of patient 914 (Averaged for Trials 1-3). 
POPULATION AVERAGE (TRIALS 1-3) STD DEVIATION (TRIALS 1-3) 
1 0.03 0.02 
2 0.27 0.11 
3 0.33 0.05 




Figure 5.19:  Filtrand extracted from patient samples (Patient 923) using nanoparticles 
having no peptide conjugates.  Population gates were copied from previous trials 
performed on untreated ascites and pure nanoparticle samples. 
 
 
Table 5.9:  % Total for each population gated on dot plots obtained from flow cytometry 
analysis of the filtrand control samples of patient 923 (Averaged for Trials 1-3). 
POPULATION AVERAGE (TRIALS 1-3) STD DEVIATION (TRIALS 1-3) 
1 0.27 0.07 
2 3.08 0.27 
3 0.24 0.03 
4 0.00 0.01 
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Demonstrating the Binding of Ovarian Cancer Cells to Peptide Conjugated Nanoparticles. 
GGGGYSAYPDSVPMMSK peptide conjugation to nanoparticles using the 
reductive amination technique described in the Methods section was verified by taking 
magnetically aggregated particles that had been cleansed in multiple washes with PBS 
and viewing them using fluorescence microscopy.  Figure 5.20 shows an aggregation of 
magnetic nanoparticles with Rhodamine-conjugated peptides viewed using an Olympus 
Rhodamine filter on an Olympus X51 inverted fluorescence microscope.  The red 
fluorescence produced by the aggregate was taken as confirmation that the peptides 
had been successfully linked.  
 
 
Figure 5.20:  Fluorescence microscopy image (20x) of superparamagnetic nanoparticles 
coated with glucuronic acid and Rhodamine-conjugated peptides taken on an Olympus 
X51, equipped with an Olympus DP-71 camera, and using an Olympus Rhodamine filter.  
The particles in this image were aggregated using a 2500 gauss magnet to enhance 
visibility. 
 
To visually confirm the adsorption of cells to the nanoparticles subsequent to 
flow cytometry analysis, a 100 µL sample of the filtrand was stained with 10 µL of 
Trypan Blue and imaged using bright field microscopy (Figure 5.21).  Having been  
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Figure 5.21:  Microscope bright field image (10x) of filtrand from ascites sample stained 
with Trypan Blue. Ascites samples had been previously stored in 10% DMSO at -80⁰C 
and would contain dead cells that would not prevent Trypan Blue from traversing their 
membranes.  In this image we see the aggregation of dead cells bound to nanoparticles 




previously stored at -80⁰C, it was assumed that the ascites samples would contain dead 
cell populations.  Dead cells can no longer inhibit the passage of Trypan Blue across the 
cell membrane and would be enhanced visually under bright field imaging using this 
technique.  A 2500 gauss magnet was used to aggregate the magnetic nanoparticles into 
large clusters to provide further image enhancement.  In Figure 5.21 the nanoparticle 
aggregate appears blue, suggesting the adherence of dead cells. 
 
Demonstrating that Peptide Conjugated Nanoparticles Can Successfully Extract Ovarian 
Cancer Cells from Human Ascites Fluid. 
 Extracted cell counts were compared between experimental and control samples 
for each patient and trial using Chi-square analysis.  The null hypothesis tested was that 
there was no significant difference between the numbers of cells collected in the 
experimental and control groups for each gated population.  The cell counts from the 
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filtrand obtained using superparamagnetic nanoparticles coated with glucuronic acid 
and conjugated to a 17 residue peptide sequence (GGGGYSAYPDSVPMMSK) made up 
the experimental data set (a) and the cell counts from the filtrand obtained using 
superparamagnetic nanoparticles coated with glucuronic acid and no peptide 
conjugates made up the control data set (c).  The minimum accepted p value of 
significance was 0.05.  If the p value was greater than 0.05 it was concluded that the 
conjugated peptide had no significant effect on the cell numbers extracted.  For p values 
lower than 0.05 we determined that cell counts were significantly enhanced using the 
peptide conjugate.  The census of each starting population was taken from the flow 
cytometry analysis of the pure ascites samples used for each trial (H1 and H0 for 
experimental and control groups respectively).  An example calculation is illustrated in 
Calculation 1 and the results from the analysis can be seen in Tables 5.10 and 5.11 for 
patients 914 and 923 respectively.  The p values for the majority of the patient trials fell 
well below 0.05 and it was concluded that the superparamagnetic nanoparticles with 
the 17 residue peptide conjugate were capable of extracting a significantly higher 
number of cells than particles with no peptide conjugates.  The only trials yielding p 
values higher than 0.05 came from population 4 of samples analyzed from patient 923.  
It was determined that any cells extracted from this population were captured non-
specifically.  
 To verify the proclivity of the 17 residue peptide (GGGGYSAYPDSVPMMSK) to 
target cell populations expressing markers commonly expressed by adenocarcinomas 
peritoneal effusions were immunostained using a panel of monoclonal antibodies  
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CALCULATION 2:  Sample calculation using Chi-square analysis to determine the statistical significance of 
cell numbers extracted using superparamagnetic nanoparticles conjugated to ephrin mimetic peptides. 
 
 CAPTURED NOT CAPTURED  
EXPERIMENTAL a b H1 
CONTROL c d H0 
 V1 V0 t 
  
 
Chi square =     (t) (ad-bc)
2 
                      (V1)( V0)( H1)( H0) 
 
Data from Trial I of the samples analyzed from Patient 914: 
 
a = 1234 (Cell count from population 1 of the filtrand obtained using nanoparticles with peptide 
conjugates) 
H1 = 6096 (Cell count from population 1 of the untreated ascites sample) 
b = H1-a = 4862 
c = 17 (Cell count from population 1 of the filtrand obtained using nanoparticles with no peptide 
conjugates) 
H0 = 6096 (Cell count from population 1 of the untreated ascites sample used to test the control) 
d = H0-c = 6079 
t = H1 + H0 = 12192 
V1 = a + c = 1251 
V0 = b + d = 10941 
 
Chi square = 1319.30 
 
Because a 2 x 2 chi square table was used the degrees of freedom (df) equaled 1.  The Chi square and df 
values were used to calculate p values. 
 
 


















1 1 114.79 8.76 x 10
-27
 1319 110 1319 0 
1 2 66.53 3.46 x 10
-16
 1543 76 1543 4 
1 3 69.33 8.34 x 10
-17
 1849 79 1849 4 
2 1 1319.30 7.25 x 10
-289 
6096 1234 6096 17 
2 2 916.94 2.04 x 10
-201 
5929 919 5929 26 
2 3 1004.24 2.15 x 10
-220 
5632 1021 5632 39 
3 1 1614.27 0.00 776 818 776 30 
3 2 771.939 6.81 x 10
-170
 725 548 725 30 
3 3 908.76 1.22 x 10
-199
 684 595 684 39 
4 1 16.66 4.50 x 10
-5
 366 19 366 1 
4 2 12.51 4.05 x 10
-4
 388 15 388 1 
4 3 19.50 1.00 x 10
-5






















1 1 88.49 5.10 x 10
-21 
1126 140 1126 24 
1 2 112.99 2.16 x 10
-26
 1095 161 1095 23 
1 3 81.09 2.16 x 10
-19
 1085 153 1085 35 
2 1 594.18 3.10 x 10
-131 
5998 1157 5998 288 
2 2 689.52 5.68 x 10
-152 
6179 1266 6179 296 
2 3 779.11 1.88 x 10
-171 
6218 1425 6218 339 
3 1 74.85 5.07 x 10
-18
 382 115 382 23 
3 2 87.38 8.95 x 10
-21
 372 123 372 22 
3 3 65.83 4.91 x 10
-16
 340 114 340 28 
4 1 3.60 0.06 470 6 470 1 
4 2 14.20 1.65 x 10
-4 
505 14 505 0 




having a high affinity for those markers.  The receptor tyrosine kinase, EphA2, is 
expressed prolifically in patients with ovarian carcinoma.
70
   Prior studies have shown 
that the peptide sequence YSAYPDSVPMMS acts as an ephrin mimetic and is highly 
selective for EphA2.
49
  It was assumed that nanoparticles functionalized with a 
derivative of this peptide sequence (GGGGYSAYPDSVPMMSK) would preferentially bind 
cells in populations testing positive for EphA2 expression.  Human epithelial antigen 
(HEA)
64
 and the extracellular domain of the MUC16 cell surface protein, CA125,
66-69
 have 
been investigated extensively as potential diagnostic aids for identifying malignant 
adenocarcinomas in serous effusions.  Human epithelial antigen (HEA) is a glycoprotein 
epitope that exhibits elevated expression levels in metastatic adenocarcinomas.
75
  Ber-
EP4 has a high affinity for HEA and is commonly used to verify HEA expression.
64
  Serum 
levels of CA125 are elevated in 90% of the patients with ovarian cancer.
76
  HEA and 
CA125 levels were expected to be elevated in the same cell populations expressing high 
levels of EphA2.  Although increased EphA2 expression has been linked to ovarian 
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carcinomas it is not exclusively expressed by this cell type.
77
  The Eph receptor family is 
one of the largest RTK families and Eph/ephrin receptor signaling is intimately coupled 
with cell movement, maintenance of cellular boundaries, and blood vessel 
remodeling.
78, 79
  An ephrin mimetic would be expected to bind any cell expressing an 
Eph receptor but it would also be expected to preferentially bind cells with higher Eph 
expression.
42
  It was postulated that EphA2 receptors or fragments may also be 
displayed by antigen presenting cells (APC).  Macrophages and dendritic cells commonly 
participate in the anti-tumor response and were expected to populate the serous 
effusions of ovarian cancer patients.
80
  If this were the case, APCs could be targeted by 
the 17 residue peptide as well.  To verify this eventuality, these effusions were also 
stained with monoclonal antibodies selective for a common dendritic cell and 
macrophage marker (CD83 and MAC387 respectively).  The cell surface molecule,CD83, 
is one of the most prominent maturation markers for fully mature dendritic cells.
81
  The 
presence of this marker in populations that also tested positive for EphA2 expression 
would help to substantiate the presence of dendritic cells presenting the EphA2 antigen.  
However, because tumor cells typically release factors that prevent dendritic cell 
maturation, low expression levels of this marker were expected.
57, 58
             
Single parameter frequency histograms were used to analyze both control and 
experimental samples.  The untreated ascites samples for each patient were used as 
control specimens and the autoflourescence levels were recorded using a four decade 
log amplifier.  Experimental samples of peritoneal effusions from each patient were 
challenged in separate trials with anti-CD83, anti-MAC387, BerEP4, anti-EphA2 and anti-
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CA125.  Each monoclonal antibody had a FITC conjugate, or a secondary antibody with a 
phycoerythrin conjugate (EphA2).  The histograms from the experimental samples were 
superimposed over those of the control to determine whether there were any variances 
between the two (Figures 5.22-5.37).  From these graphs we can see that 0.22% (Figure 
5.23) of the 10,000 events counted for patient 914 samples showed a positive 
expression for the EphA2 receptor and occurred in gated population P1.  The values for 
P2, P3 and P4 were 16.15% (Figure 5.25), 12.87% (Figure 5.27), and 0.30% (Figure 5.29) 
respectively.  The percentages showing positive EphA2 expression in the samples from 
patient 923 were 0.36% (Figure 5.31, gate P1), 5.60% (Figure 5.33, gate P2), 2.71% 
(Figure 5.35, gate P3), and 0.58% (Figure 5.37, gate P4).  The covariance between the 
expression levels of EphA2 and CA125 appear to be positive in gated populations P1, P2, 
and P3 (Figure 5.22-5.27) of samples from patient 914 and gated populations P1, P2, P3, 
and P4 (Figure 5.30-5.37) of samples from patient 923.  For instance, CA125 and EphA2 
were expressed negligibly in P1 of samples from patient 914 (0.16% and 0.22% 
respectively, Figure 5.22 and 5.23) and in greater numbers (30.90% for CA125 and 
16.15% for EphA2) in gated population P2 (Figure 5.24 and 5.25).  The highest number 
of cells expressing CA125, EphA2, HEA, and MAC387 came from gates P2 and P3 for 
samples from patient 914 (Figure 5.24-5.27).  However, infrequent HEA expression was 
seen correspondingly as 1.43% and 0.75 % in both these populations.  For samples from 
patient 923 the number of cells expressing HEA was 8.06% for P2 (Figure 5.32) and 
1.52% for P3 (Figure 5.34).  There was also a positive covariance between the number of 
cells expressing EphA2, HEA, CA125, and MAC387 in P2, P3, and P4 (Figure 5.32-5.36) 
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and the highest numbers of cells expressing these markers came from P2 (Figure 5.32 
and 5.33). 
 As expected, the expression levels of CD83 were very low for both patient 
samples.  The average CD83+ cell count across all four populations in samples from 
patient 914 was 0.12% +/- 0.14%  (mean +/- standard deviation) and 0.19% +/- 0.28% for 























Figure 5.22:  Patient sample 914 was stained with a panel of FITC-conjugated 
monoclonal antibodies.  The cell counts and fluorescent intensities for cells testing 
positive in P1 are compared to autofluorescent levels in a sample of unstained ascites.  
 
 
Figure 5.23:  Patient sample 914 was stained with PE-conjugated anti-EphA2.  The cell 
counts and fluorescent intensities for cells testing positive in P1 are compared to 





Figure 5.24:  Patient sample 914 was stained with a panel of FITC-conjugated 
monoclonal antibodies.  The cell counts and fluorescent intensities for cells testing 
positive in P2 are compared to autofluorescent levels in a sample of unstained ascites.  
 
 
Figure 5.25:  Patient sample 914 was stained with PE-conjugated anti-EphA2.  The cell 
counts and fluorescent intensities for cells testing positive in P2 are compared to 




Figure 5.26:  Patient sample 914 was stained with a panel of FITC-conjugated 
monoclonal antibodies.  The cell counts and fluorescent intensities for cells testing 
positive in P3 are compared to autofluorescent levels in a sample of unstained ascites.  
 
 
Figure 5.27:  Patient sample 914 was stained with PE-conjugated anti-EphA2.  The cell 
counts and fluorescent intensities for cells testing positive in P3 are compared to 




Figure 5.28:  Patient sample 914 was stained with a panel of FITC-conjugated 
monoclonal antibodies.  The cell counts and fluorescent intensities for cells testing 
positive in P4 are compared to autofluorescent levels in a sample of unstained ascites.  
 
 
Figure 5.29:  Patient sample 914 was stained with PE-conjugated anti-EphA2.  The cell 
counts and fluorescent intensities for cells testing positive in P4 are compared to 





Figure 5.30:  Patient sample 923 was stained with a panel of FITC-conjugated 
monoclonal antibodies.  The cell counts and fluorescent intensities for cells testing 
positive in P1 are compared to autofluorescent levels in a sample of unstained ascites.  
 
 
Figure 5.31:  Patient sample 923 was stained with PE-conjugated anti-EphA2.  The cell 
counts and fluorescent intensities for cells testing positive in P1 are compared to 





Figure 5.32:  Patient sample 923 was stained with a panel of FITC-conjugated 
monoclonal antibodies.  The cell counts and fluorescent intensities for cells testing 




Figure 5.33:  Patient sample 923 was stained with PE-conjugated anti-EphA2.  The cell 
counts and fluorescent intensities for cells testing positive in P2 are compared to 





Figure 5.34:  Patient sample 923 was stained with a panel of FITC-conjugated 
monoclonal antibodies.  The cell counts and fluorescent intensities for cells testing 
positive in P3 are compared to autofluorescent levels in a sample of unstained ascites.  
 
 
Figure 5.35:  Patient sample 923 was stained with PE-conjugated anti-EphA2.  The cell 
counts and fluorescent intensities for cells testing positive in P3 are compared to 




Figure 5.36:  Patient sample 923 was stained with a panel of FITC-conjugated 
monoclonal antibodies.  The cell counts and fluorescent intensities for cells testing 
positive in P4 are compared to autofluorescent levels in a sample of unstained ascites.  
 
 
Figure 5.37:  Patient sample 923 was stained with PE-conjugated anti-EphA2.  The cell 
counts and fluorescent intensities for cells testing positive in P4 are compared to 






 In our previous study, we demonstrated that ovarian cancer cells could 
be selectively removed from the peritonea of mice using magnetic nanoparticles 
conjugated to a derivative of the ephrin mimetic peptide YSAYPDSVPMMS.  Based on 
these results we proposed that our technique might be employed as a viable modality 
for preventing the metastatic spread of carcinoma cells in ovarian cancer patients.
42
  In 
this study, we provide further evidence of this possibility by demonstrating that ovarian 
cancer cells can be selectively removed from human peritoneal effusions using 
superparamagnetic nanoparticles conjugated to the ephrin mimetic peptide 
GGGGYSAYPDSVPMMSK.  The EphA2 receptor has been previously shown to be highly 
expressed in ovarian cancer cells and to bind specifically to the YSAYPDSVPMMS 
peptide.   
Flow cytometry was used to analyze ascites samples from two patients 
diagnosed with late stage serous papillary ovarian cancers.  Bivariate displays of forward 
and side scatter patterns obtained from sample analyses were examined and visually 
discreet regions were gated.  The number of cells isolated using the peptide conjugated 
nanoparticle was highly significant relative to non-conjugated particles (p < 0.01, Chi-
square test).  As a further test of the effectiveness of our method, we looked for a 
correlation between the cells extracted and the expression of EphA2.  We found that for 
both patient samples the highest numbers of cells were extracted from the populations 
having the highest numbers of cells expressing EphA2 and there was a positive 
covariance between these variables in all four populations. 
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To validate that the extracted cells expressing EphA2 were ovarian cancer cells, 
we tested for the presence of two additional established markers of ovarian cancer 
cells.  We found that all three markers were significantly expressed in the human ascites 
cell populations where we were able to extract significantly large numbers of cells using 
the peptide conjugated nanoparticles.  Collectively our findings are consistent with the 
hypothesis that magnetic nanoparticles with ligands having a high affinity for antigens 
expressed on ovarian cancer cells can be used to isolate free floating cancer cells from 
the peritoneal fluid.  Since it is widely acknowledged that these free floating ovarian 
cancer cells are responsible for the majority of ovarian cancer metastases, it is our hope 
that our method may eventually be applied to clinical practice with therapeutic benefit.     
 
         





OVARIAN CANCER SURVIVAL STUDY 
Introduction  
 Another important progression from our initial capture studies was the 
validation as to whether the proposed cell capture modality would be successful at 
prolonging the lives of patients afflicted with ovarian carcinomas.  To move toward that 
goal the therapy would need to be tested against a metastatic ovarian cancer animal 
model.  To date, many groups have found that while the development of subcutaneous 
tumors in animal models can be facile the development of a metastatic model is much 
more challenging.  Coupled with the difficult development issues comes the equally 
difficult task of monitoring the dissemination of micrometastases which can often 
remain outside the range of detectability.  The ideal model would be comprised of 
tumorogenic cells with a high proliferative potential.  The proliferation would also need 
to be measurable both qualitatively and quantitatively. 
The Model     
 Vascular endothelial growth factor (VEGF) is a growth factor involved in 
angiogenesis.  A constant blood supply is critical to the rapid expansion of highly prolific 
cell lines.  Malignant cell lines have this need and their expansive potential is increased 
by high levels of this growth factor.  In an effort to develop an ovarian cancer cell line 
with high proliferation potential, Zhang et al. transfected a murine ovarian cancer cell 
line (ID8) with the gene for VEGF expression.
35
  The cell line was also transfected with 
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the gene for green fluorescent protein (GFP) expression, which has become a common 
technique for monitoring the metastatic spread of malignant cells.  The modified ID8 cell 
line (ID8 GFP VEGF) had two advantages.  By expressing its own copies of the VEGF 
protein it could stimulate angiogenesis and thereby increase the proximitive blood 
supply.  By expressing GFP its dissemination could be visibly monitored.  It had even 
been shown that the presence of GFP in cells could be quantitatively measured by 
taking optical density measurements using a microplate reader.
37
  Combining the ID8 
GFP VEGF cell line with the analytical technique gave us the highly proliferative and 
traceable cell line we were seeking.   
 Prior to employing the model we would need to test it and establish our data 
points.  Mimicking the published model of Zhang et al. we resolved to inoculate 6-7 
week old female C57BL/6 mice with the ID8 GFP VEGF cell line.  A control group of the 
same age and breed was inoculated with and ID8 cell line expressing only GFP (ID8 GFP).  
Comparing the progression of the two cell lines helped us to establish average longevity 
and work out a method for quantifying the number of metastases.  Many of the 
specifics of testing this model have already been covered in Chapter 2.  As previously 
mentioned, 4 mice from each of the ID8 GFP and ID8 GFP VEGF groups would be 
analyzed at 4 different time points (2,4,6, and 8 weeks).  The external ventral region 
around the peritoneum was photographed using bright field to log either the existence 
of or lack of visible tumors.  Each mouse was then necropsied.  The peritoneal cavity 
was exposed and photographed using bright and dark field microscopy with the 
peritoneal wall intact.  Figure 6.1.A and 6.1.B were taken at week 4 of a mouse from the 
ID8 GFP group.  Figure 6.2.A
GFP VEGF group.  The dark field exposures were excited at 4
are visible in Figure 6.2.B.  The liver, lung, spleen,
peritoneal wall were remov





Figure 6.1:  Panel of bright field and dark field images taken of a necropsied mouse from 




 and 6.2.B were taken at week 4 of a mouse from the ID8 
88 nm and metastatic sites 
 and a 1 cm X 1 cm section of the 





























Figure 6.2:  Panel of bright field and dark field images taken of a necropsied mouse from 


























and continual contact with the peritoneal fluids.  The representative photos taken from 
mice in the ID8 GFP group at week 4 are featured in Figure 6.1.C-6.1.J.  There is no 
significant visible fluorescence in any of the dark field photos which would indicate that 
the ID8 GFP line is not well established or has not localized in any of the observed 
regions.  Representative photos taken from mice in the ID8 GFP VEGF group at week 6 
are featured in Figure 6.2.C-6.2.J.  There appear to be visible indications of metastatic 
sites on the liver (Figure 6.2.D) and a possibly subcutaneous tumor nodule in the 
peritoneal wall section (Figure 6.2.J) that was probably near the injection site.  An 
interesting observation is the large difference between the sizes of the spleens taken 
from the control and experimental groups.   The experimental group spleen (Figure 
6.2.H) appears significantly larger than the control.  The visual evidence from week 4 
appeared to indicate that the ID8 GFP VEGF proliferation was more expansive than that 
of the control. 
 To obtain a more quantitative comparison of the expansive nature of the two 
cell lines, the excised tissues and organs were homogenized and the slurry produced 
was analyzed for optical density.  The results of the optical density measurements 
obtained for the organs and tissues from each mouse analyzed in both the control and 
experimental groups presented in Figures 6.3.A-6.3.E.  The standard deviation for the 
four trials is included in the plot and the data was normalized to optical density per mg 
of organ or tissue.  The data from these graphs illustrates that by week 4 the ID8 GFP 
VEGF cell line was more prolific than the control.  The bright field and dark field 




Figure 6.3:  Week 4 comparisons of optical density measurements taken on tissues and 
organs removed from ID8 GFP and ID8 GFP VEGF groups.
 
 
groups at Week 6 are featured in Figures 6.4.A
the expansive potential of the ID8 GFP VEGF cell line over that of the ID8 GFP group is 
visibly apparent when comparing the dark field images of the exposed peritonea



















Figure 6.4:  Panel of bright field and dark field images taken of a necropsied mouse from 





























Figure 6.5:  Panel of bright field and dark field images taken of a necropsied mouse from 





Dark field (488 nm excitation
mesenchyme covering peritoneum.  
Extensive fluorescent regions are believed 
























 The study could not be carried to week 8 because all the members of the ID8 
GFP VEGF group had either died or had to be euthanized because of the accumulation of 
large volumes of ascites (≥ 150% of body mass).  This result gave us the expected 
average mortality date for the ID8 GFP VEGF group.  It was also clear from the continual 
accumulation of ascites throughout the group after week 4 that weight gain could be 
used as a non-invasive means to monitor metastatic progression. 
Therapy 
 Having grasped the mechanics of our metastatic model and planned a strategy 
for data collection I moved on to working out the logistics of the therapeutic system.  As 
mentioned in Chapter 2, three elimination methods were considered for removing the 
MNPs.  The method illustrated in Figure 6.6.A involved infusing the mice 
intraperitoneally with the MNPs, allowing the MNPs to circulate in the peritoneal cavity, 
and eventually removing them with the circulatory pump.  The design was first tested 
on a nu/nu 6 month old mouse that had never been injected with an ovarian cancer cell 
line.  The extracorporeal circuit was first primed with a sterile PBS buffer solution and 
the mouse was cannulated in the ventral surface of the peritoneum with a 21.5 gauge 1” 
needle (inlet).  The outlet needle was submerged into a vial of sterile PBS and the pump 
was engaged at a flow rate of 2 mL/min until 7 mL of the sterile PBS had been pumped 
into the peritoneal cavity of the mouse.  The pump was disengaged and the outlet 
needle was used to cannulate the mouse toward the lower right flank of the peritoneal  
A:  Extracorporeal circuit and pump.
C:  Photo taken 4 days postoperatively of mouse 
showing no signs of complications from the 
procedure. 
 
Figure 6.6:  Preliminary study performed to assess the viability of eliminating magnetic 
nanoparticles from the peritoneum of a mouse using an extracorporeal circuit, magnet, 
and peristaltic pump.  
 
 
cavity (Figure 6.6.A).  The mouse was then injected IP with 100 µL of MNPs coated wit
polygalacturonic acid and having
was massaged for 1 min to disseminate the MNPs throughout the per




B:  Arrow indicates nanoparticles that 
collected in section of tubing that was 
placed over a 2500 Gauss neodymium 
magnet. 
 
D:  Arrow indicates small br
needle perforated skin. Photo taken 4 
days postoperatively.
 
 no functional conjugates.  The abdomen of the mouse 







minutes.  The inlet needle was removed from the peritoneum and place in a graduated 
cylinder where it remained until 7 mL of fluid had filled the cylinder.  Figure 6.6.B shows 
the magnetic nanoparticles that collected in the section of tubing bound to the 2500 
gauss neodymium magnet.  The mouse was monitored for 4 days postoperatively and 
appeared to show no serious signs of complications from the procedure (Figure 6.6.C-
6.6.D).   
 A similar procedure (Figure 6.7.A-6.7.B) was performed on a residual member of 
the ID8 GFP control group that had survived out to week 10 in the previously described 
metastatic model test.  This mouse however was injected with 100 µL of MNPs (1 
mg/mL) that were coated with glucuronic acid and conjugated to the YSA peptide.  The 
cycle time on the pump was increased from 3 to 10 min and three glass capillary tubes 
measuring 7 in were attached to the circuit and placed between two stacked 6000 gauss 
neodymium magnets to increase the exposure time of the MNPs to the magnetic field.  
At no point during the test were particles seen collecting in the capillary tubes (Figure 
6.7.B).  The mouse was necropsied postoperatively and it was discovered that the 
peritoneum of the mouse contained a great deal of malignant growth.  The particles had 
aggregated densely in the malignant material (Figure 6.7.C-6.7.D ).  This discovery 
suggested that particles injected IP might bind to internal tumor sites and not be able to 
be non-invasively eliminated.  To prevent this eventuality the experiment was repeated 
with a single modification.  An external 25 mL mixing vial was added to the circuit where 
the particles could be injected and contact the cells for an extended period without 
needing to enter the peritoneum (Figure 6.8.A-6.8.B).  Figure 6.8.C shows that the  
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Figure 6.7:  Elimination of magnetic nanoparticles injected IP.  A:  Schematic for particles 
being delivered IP. B:  Photo of actual setup. C:  View of exposed peritoneal region 
postoperatively.  Arrow points to accumulation of particles on tumor mass.  D:  Excised 
tumor mass bound to MNPs.  Tissues could be moved around using a magnet. 
 
 
particles were successfully captured in the capillary tubing but it was noticed that the 
particles would occlude the capillary and the fluid pressure would break them free 
returning them to circulation and possibly to the peritioneum.  It was this last 
observation that prompted the development of mechanism fully detailed in Chapter 2 
(Figure 2.10).  In this final embodiment the capillary tubes were supplanted with a 15 
mL glass vial that would be strapped to the side of the 6000 gauss magnet.  This version 










Figure 6.8:  Using magnetic nanoparticles to externally remove cancer cells injected IP.  
A:  Schematic for particles remaining external B:  Photo of actual setup.  The arrow is 
pointing to the external chamber where the MNPs have been added.  C:  View of 
particles sequestered by magnets.  D:  Mixing cartridge sitting on top of magnet.  Arrow 
indicates the accumulation of magnetized cells at the bottom of the vial. 
 
 
been injected IP with 7 million ID8 GFP VEGF cells.  The magnetic filtrand that collected 
in the vial attached to the magnet was inspected using fluorescent microscopy after 
being washed 3x with distilled water.  Figure 6.9.A shows a bright field image of the 
magnetic filtrand that was collected.  Figure 6.9.B shows the magnetic filtrand collected 
using dark field microscopy (488 nm excitation).  The GFP expressing cells are seen in 







Figure 6.9:  Magnetic filtrand retrieved from magnetic filter.  A: Bright field image (10x). 





     The data from testing the metastatic model and the preliminary engineering 
studies completed on the design of the therapeutic system left us with a viable means of 
testing the efficacy of magnetic capture as a means of preventing metastatic growth and 
improving longevity.  This study is currently ongoing.  The system implemented appears 
to be filtering metastatic cells from the peritoneal cavity of the mice but how this will 
affect longevity cannot be emphatically determined until the experimental group passes 








HIV-1 Capture Study 
 The Zeptometrix HIV-1 p24 Antigen ELISA would be used to determine the 
successful capture of the HIV-1 virus using magnetic nanoparticles.  Prior to performing 
the capture study two experiments were run to determine whether the magnetic 
nanoparticles would interfere with the performance of the ELISA.  A standard procedure 
with the HIV-1 p24 Antigen ELISA involves running an included known standard at 
various concentrations and generating a calibration curve to interpolate experimental 
sample results.  The standards were run as they would be normally but a second row of 
standards containing magnetic nanoparticles were run and the results of both were 
compared.  The manual for the ELISA states that the optical density measurement for 
the standard having a p24 concentration of 62.5 pg/mL should be above 0.5 and the 
optical density measurement for the standard having a p24 concentration of 0.0 pg/mL 
should be less than 0.2 for the test to be valid.  Two trials were run and in the first trial 
1.34 x 10
4
 magnetic nanoparticles coated with glucuronic acid and having no antibody 
conjugates were added to the standard wells in the experimental row.  In the second 
trial 6.69 x 10
13 
magnetic nanoparticles were added.  The optical density measurements 






Table A.1:  Results from tests conducted to determine whether the magnetic 
nanoparticles would interfere with the normal function of the ELISA assay. 




62.5 pg/mL 0.6740 0.5690 
0.0 pg/mL 0.0330 0.0290 
 




62.5 pg/mL 0.8070 0.7810 
0.0 pg/mL 0.0070 0.0080 
 
 In both trials the optical density measurements were within the acceptable 
range.  It should be noted however that the presence of the magnetic nanoparticles may 
have accounted for the slightly lower measurements obtained.  
 
Capture Study Design 
 The capture study is visually represented in Figure A.1.  In this study the HIV-1 
virus was obtained from a stock sample and the concentration was brought within the 
detectable range of the HIV-1 p24 Antigen ELISA.  After diluting the viral sample it was 
aliquoted into equal volumes in three separate vials.  Vial 1 was set aside for testing 
using the ELISA assay and would serve as a control.  Vial 2 was used to perform a viral 
extraction using magnetic nanoparticles having no antibody conjugates.  This vial would 
serve as another control.  Vial 3 was used to perform a viral extraction using magnetic 
nanoparticles conjugated with anti-HIV-1 gp120.  This was the experimental group.  Two 
successful experiments were run using different conditions.  The conditions and data 
have been summarized in Table A.2 and Figure A.2 for the first experiment. 
 In the second experiment some of the conditions were changed and four vials 
were tested.  Vials 1 and 2 were still control vials and Vial 3 and Vial 4 were 
experimental vials receiving different concentrations of magnetic nanoparticles with the  
 









# of Magnetic Nanoparticles Introduced (NO 
Antibody Conjugates) Vial 2 
# of Magnetic Nanoparticles Introduced (WITH 
Antibody Conjugates) Vial 3 
Viral Particles in Sample 
Average  p24 Concentration in Vial 1 (average of 2 
trials) 
Average  p24 Concentration in Vial 2 (average of 6 
trials) 






-1 Capture Study. 












53.197 +/- 5.130 (mean +/- standard deviation)
53.360 +/- 2.495 (mean +/- standard deviation)








Figure A.2:  Data for HIV-1 Capture Study Experiment I. 
 
 
antibody conjugate.  Table A.3 and Figure A.3 summarize the data obtained from this 
experiment. 
 
Table A.3:  Summary of conditions and results for HIV-1 Capture Study Experiment II. 
CONDITION VALUE 
Temperature 37° C 
Incubation Time 30 min 
Extraction Time 10 min 
# of Magnetic Nanoparticles Introduced (NO 




*Note- this is a order of magnitude greater than 
the previous experiment 
# of Magnetic Nanoparticles Introduced (WITH 




# of Magnetic Nanoparticles Introduced (WITH 




Viral Particles in Sample 55,000 
Average  p24 Concentration in Vial 1 (average of 2 
trials) 
58.845 +/- 1.420 (mean +/- standard deviation) 
Average  p24 Concentration in Vial 2 (average of 6 
trials) 
48.366 +/- 4.247 (mean +/- standard deviation) 
Average  p24 Concentration in Vial 3 (average of 6 
trials) 
46.141 +/- 2.771 (mean +/- standard deviation) 
Average  p24 Concentration in Vial 4 (average of 6 
trials) 
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Figure A.3:  Data for HIV-1 Capture Study Experiment II. 
 
 
(NOTE - The average number of antibodies conjugated to each nanoparticle in 
Experiments 1 & 2 was calculated to be approximately 14.) 
 
Discussion: 
 The results from the first extraction experiment show a difference between the 
average starting p24 concentration (53.197 +/- 5.130) and the average concentration of 
the experimental trials (47.498 +/- 2.7333) of 5.699 +/- 5.813.  This represents a 
reduction in p24 concentration of 10.713% +/- 10.976% in the experimental group.  In 
the second extraction experiment a 17.811% +/- 7.622% reduction in p24 concentration 
is shown for the control trial.  This may be attributable to the increased incubation time 
(i.e. 30 min), the incubation temperature (i.e. 37° C), non-specific binding (i.e. hydrogen 
bonding), or the interference of particles that remained in the sample with the ELISA 
assay.  A 21.592% +/- 5.317% (50 µL trial) and 61.845% +/- 5.206% (100 µL trial) 
reduction was seen in the experimental trials.  Using the highest p24 concentration from 
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from trial 6 of the control group (41.779 pg/mL), and the lower concentration of the 
initial p24 concentration (57.842 pg/mL) as our starting concentration we calculated a 
Chi-square value of 9.712 and a p-value of 0.002.  This p-value exceeds a 99% 
confidence interval and indicates significant levels of p24 reduction for the 100 µL 
experimental group.  The fact that Vial 3 showed a greater reduction in p24 
concentration than the control group (Vial 2) and that the nanoparticle count used in 
Vial 2 (6.69 x 10
14
 ) significantly outnumbered the count used in Vial 3 (3.52 x 10
12
 ) also 
makes the possibility that p24 concentration was only reduced by interference (i.e. 
competitive inhibition) improbable.  The preliminary data seems to indicate that the 
antibody conjugates do aid in reducing viral titer but many more studies are necessary 
to determine whether this approach could be a viable therapy. 
Reaction Impedance Study 
 Various conditions can affect the speed of a chemical reaction.  These conditions 
can include the presence of a catalyst, temperature, the physical state of the reactants, 
or the concentration of the reactants.  Manipulation of any of these conditions can 
effectively throttle the reaction kinetics.  In an equilibrium reaction increasing reaction 
concentration can shift the reaction balance in favor of product formation and 
increasing product concentrations or decreasing reactant concentrations can impede 
product formation.  In general, it is a difficult endeavor to separate reactants from a 
reaction ad libitum but using magnetic nanoparticles provides a novel approach to do 
just that.  Conjugating magnetic nanoparticles to one of the reactants allows the 
reactant to be selectively removed from the reaction and returned if necessary at a 
distant time point.  This brief chapter describes a proof of concept that visually shows 
what I have proposed.  Magnetic nanoparticles were conjugated to a reactant in a 
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chemiluminescent reaction to show that the production of light could be controlled at 
will. 
Results and Discussion 
 The methods by which one produces chemiluminescence have been well 
researched and it was not necessary to reinvent them.  Our goal was to use an already 
established means of producing a high quantum yield of light over a sufficient duration 
and modify that mechanism by introducing MNPs, thereby providing a means of 
controlling the progression of the reaction.  Figure A.4 illustrates one mechanism that  
 
 
Figure A.4:  Chemiluminescent reaction involving luminol. 
 
uses luminol to produce light.  The mechanism was studied to determine which reagent 
could serve as a particle conjugate and act to manage the reaction kinetics. 
 Two strategies were proposed.  The first purported that the MNP could be used 
to control the reagents involved in the oxidation of the deprotonated hydroxyl groups 
on the dianon to carboxyl groups.  The reaction would need to run in alkaline solution 
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and this would mean that the hydroxyls on the MNP surface should be deprotonated.  If 
potassium oxide were used as an oxidant it was conceivable that the MNP anions would 
substitute for the oxide in KO2 releasing oxygen into the solution.  We found no 
precedents for using potassium hydroxide as an oxidant in this particular reaction so we 
estimated the ratios of reagents needed until we found a suitable mix.  1 mg of luminol 
was dissolved in 20 mL of 5 M NaOH and 10 mg of potassium hydroxide was added to 
the solution.  The MNPs were mixed in 5 M NaOH separately for about 10 minutes to 
deprotonate the surface hydroxyls and then the particles were added to the solution 
containing luminol.  The problem with this approach was that potassium oxide was 
practically insoluble in the alkaline solution and continually precipitated out.  However, 
it was noted that upon adding the MNPs, bubbling was immediately observed from the 
precipitate and light was produced.  The solubility issue with the potassium oxide 
caused us to quickly abandon this approach and seek another.   
 Further inspection of the reaction scheme in Figure A.2 lead me to believe that it 
might be possible to use luminol’s primary amine as a conjugation point.  It did not 
appear to be playing any role in the production of light but this was verified through a 
literature search.  Conjugating the MNP to luminol would mean that luminol could be 
extracted from the reaction at any point prior to completion.  To conjugate luminol to 
the MNP surface, carboxyl groups were first added using a 100-fold molar excess of 
terepthalic acid.  The 1:100 molar ratio was used to limit polymerization and insure that 
free carboxyls would be present to form amide bonds with the primary amine of 
luminol. 
 Initially it was unclear whether the luminosity of luminol’s emissions would be 
dependent on the polarity of the solvent.  This was tested by running the experiments in 
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methanol, ethanol, and distilled water.  Unaided visible emissions were observed in 
each case.  However, one unusual difference was discovered. 
 UV/Vis spectroscopy was used to follow the conjugation process and spectra of 
unconjugated luminol were observed in three different solvents; methanol, ethanol, and 
distilled water (Figure A.5-A.7).  The conjugation procedure was carried out by binding 
terepthalic acid to the surface of the particle that could in turn bind luminol.  Spectra of 
these conjugates were observed as well.  Strangely, the samples containing pure luminol 
in aqueous solution showed a shift into the UV range.   This shift was also seen post 
conjugation to the magnetic particles.  A literature search provided an explanation for 
the phenomena.  Ghoheim et al. 
82
 had observed a red shift in the fluorescent spectrum 
of luminol when it went from a polar to non-polar solvent.  It was resolved that this was  
 
Figure A.5:  UV/Vis spectrum for luminol dissolved in ethanol. 
 





























Figure A.6:  UV/Vis spectrum of luminol dissolved in aqueous solution. 
 
a result of the stabilization of the excited states in the polar solvent.  Luminol emissions 
were a direct result of the hydrogen bonds formed with the solvent.
83
  This effect 
enabled me to use fluorescent microscopy as an additional means of verifying luminol’s 
conjugation to the particle surface. 
 





























Figure A.7:  UV/Vis spectrum of luminol dissolved in methanol. 
 
 Once it was evident that the luminol had been successfully conjugated to the 
MNP, it was necessary to verify its ability to impede reaction progression.  A procedure 
was found for using luminol to produce visible light that involved diluting household 
bleach in distilled water at a ratio of 10 mL/1 L respectively.  10 mL of the diluted bleach 
was then added to 5 mL of 0.1 M NaOH in a clear 25 dram glass vial.  A 2000 gauss 
magnet was placed at the side of the vial and the lights were turned out in the 
laboratory.  100 µL of the luminol/MNP conjugate was added to the solution in the glass 
vial and a blue light was immediately apparent that quickly left the solution and 
aggregated on the side of the vial where the magnet had been placed.  If the 
particle/luminol aggregate was pulled from the solution by sliding the magnet above the 
solution line prior to the reaction running its course the light was no longer visible.  
Pulling the particles back into solution continued the light production process around 
the aggregate.  The experiment verified that we had developed a simple means of 





























controlling reaction kinetics.  However, the main caveat would be that the success of 
the approach would depend on the conjugability of the particle to a reagent in a manner 
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